ASLAN Pharmaceuticals (ASLN) 6-K 11 Aug 23 2023 Q2 Aslan Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2023
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Registrant Name	ASLAN PHARMACEUTICALS LIMITED
Entity Central Index Key	0001722926
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents (Note 6)	$ 40,943,949	$ 56,902,077
Trade receivable (Note 7)	12,000,000
Other assets (Note 8)	2,135,067	3,976,350
Total current assets	55,079,016	60,878,427
NON-CURRENT ASSETS
Investment in associate company (Notes 9 and 10)	0	8,587
Property, plant and equipment	39,868	43,140
Right-of-use assets	83,197	249,601
Intangible assets	3,776	5,836
Total non-current assets	126,841	307,164
TOTAL ASSETS	55,205,857	61,185,591
CURRENT LIABILITIES
Trade payables (Note 11)	6,304,936	12,784,485
Other payables (Note 11)	2,413,569	2,325,038
Lease liabilities - current	68,214	215,671
Current borrowings (Note 12)	13,382,359	7,748,831
Financial liabilities at fair value through profit or loss (Note 20)	2,189,409	90,213
Total current liabilities	24,358,487	23,164,238
NON-CURRENT LIABILITIES
Long-term borrowings (Note 12)	24,476,535	29,656,133
Total non-current liabilities	24,476,535	29,656,133
TOTAL LIABILITIES	48,835,022	52,820,371
EQUITY ATTRIBUTABLE TO STOCKHOLDERS OF THE COMPANY
Ordinary shares (Note 13)	63,700,842	63,019,962
Capital surplus	242,233,536	223,910,955
Accumulated deficits	(299,384,595)	(278,386,749)
Other reserves	(178,948)	(178,948)
Total equity attributable to stockholders of the Company	6,370,835	8,365,220
Equity/(Capital deficiency)	6,370,835	8,365,220
TOTAL LIABILITIES AND EQUITY	$ 55,205,857	$ 61,185,591

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Loss - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Statement Of Comprehensive Income [Line Items]
NET REVENUE (Note 23)	$ 12,000,000
GROSS PROFIT	12,000,000
OPERATING EXPENSES (Notes 14)
General and administrative expenses	(6,814,831)	$ (4,855,050)
Research and development expenses	(25,652,648)	(19,339,045)
Total operating expenses	(32,467,479)	(24,194,095)
LOSS FROM OPERATIONS	(20,467,479)	(24,194,095)
NON-OPERATING INCOME AND EXPENSES
Other income	134	156,749
Interest income	393,458	43,797
Impairment loss of associate accounted for using equity method		(50,109)
Other gains and losses	1,351,720	344,683
Finance costs	(2,202,341)	(1,960,321)
Total non-operating expenses	(457,029)	(1,465,201)
Share in losses of associated company, accounted for using equity method	(8,587)	(312,372)
LOSS BEFORE INCOME TAX (Note 14)	(20,933,095)	(25,971,668)
INCOME TAX EXPENSE (Note 15)	(64,751)
NET LOSS FOR THE PERIOD	(20,997,846)	(25,971,668)
Items that will not be reclassified subsequently to profit or loss:
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	(20,997,846)	(25,971,668)
NET LOSS ATTRIBUTABLE TO
Stockholders of the Company	(20,997,846)	(25,971,668)
NET LOSS FOR THE PERIOD	(20,997,846)	(25,971,668)
TOTAL COMPREHENSIVE LOSS ATTRIBUTABLE TO
Stockholders of the Company	(20,997,846)	(25,971,668)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ (20,997,846)	$ (25,971,668)
LOSS PER ORDINARY SHARE (Note 16)
Basic	$ (0.05)	$ (0.07)
Diluted	(0.05)	(0.07)
American Depositary Share
LOSS PER ORDINARY SHARE (Note 16)
Basic	(1.34)	(1.86)
Diluted	$ (1.34)	$ (1.86)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($)	Total	Ordinary Shares	Capital Surplus	Capital Surplus Ordinary Surplus	Capital Surplus Share Options Reserve	Capital Surplus Equity Instruments	Capital Surplus Other	Accumulated Deficit	Unrealized Valuation Loss on Financial Assets at Fair Value Through Other Comprehensive Income
Beginning balance at Dec. 31, 2021	$ 57,303,743	$ 63,019,962	$ 221,467,061	$ 213,098,729	$ 8,323,753		$ 44,579	$ (227,004,332)	$ (178,948)
Beginning balance, shares at Dec. 31, 2021		348,723,365
Recognition of employee share options by the Company (Note 17)	1,336,637		1,336,637		1,336,637
Net loss	(25,971,668)							(25,971,668)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	(25,971,668)							(25,971,668)
Ending balance at Jun. 30, 2022	32,668,712	$ 63,019,962	222,803,698	213,098,729	9,660,390		44,579	(252,976,000)	(178,948)
Ending balance, shares at Jun. 30, 2022		348,723,365
Beginning balance at Dec. 31, 2021	57,303,743	$ 63,019,962	221,467,061	213,098,729	8,323,753		44,579	(227,004,332)	(178,948)
Beginning balance, shares at Dec. 31, 2021		348,723,365
Ending balance at Dec. 31, 2022	8,365,220	$ 63,019,962	223,910,955	213,098,729	10,767,647		44,579	(278,386,749)	(178,948)
Ending balance, shares at Dec. 31, 2022		348,723,365
Recognition of employee share options by the Company (Note 17)	1,212,832		1,212,832		1,212,832
Issuance of new share capital	5,854,531	$ 680,880	5,173,651	5,173,651
Issuance of new share capital, shares		68,088,015
Issuance of Pre-Funded Warrant (Notes 13 and A)	8,262,698		8,262,698			$ 8,262,698
Issuance of Tranche Warrants (Notes 13 and A)	3,712,402		3,712,402			3,712,402
Transaction costs attributable to the issuance of ordinary shares (Note A)	(39,002)		(39,002)	(39,002)
Net loss	(20,997,846)							(20,997,846)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	(20,997,846)							(20,997,846)
Ending balance at Jun. 30, 2023	$ 6,370,835	$ 63,700,842	$ 242,233,536	$ 218,233,378	$ 11,980,479	$ 11,975,100	$ 44,579	$ (299,384,595)	$ (178,948)
Ending balance, shares at Jun. 30, 2023		416,811,380

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical)	6 Months Ended
	Jun. 30, 2023 USD ($)
Net Proceeds from offering of shares	$ 21,255,809
Financial liabilities measured at fair value through profit or loss	3,465,180
Private Placement
Net Proceeds from offering of shares	19,994,760
ATM Offering
Net Proceeds from offering of shares	$ 1,261,049

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before income tax	$ (20,933,095)	$ (25,971,668)
Adjustments for:
Depreciation expenses	178,787	140,492
Amortization expenses	2,060	2,060
Net gain on fair value changes of financial assets and liabilities measured at fair value through profit or loss	(1,365,984)	(104,001)
Finance costs	2,202,341	1,960,321
Interest income	(393,458)	(43,797)
Compensation costs recognized of share-based payment transactions	1,457,192	955,673
Share of loss of associates accounted for using equity method	8,587	312,372
Impairment loss of associate accounted for using equity method		50,109
Net gain on fair value changes of short-term investments measured at fair value through profit or loss		(30,846)
Unrealized gain on foreign exchange, net	(125,279)	(344,266)
Changes in operating assets and liabilities
Increase in trade receivable	(12,000,000)
Decrease in other assets	1,840,032	1,368,600
Increase/(Decrease) in trade payables	(6,479,549)	6,326,120
Decrease in other payables	(159,081)	(577,153)
Cash used in operations	(35,767,447)	(15,955,984)
Interest received	114,302	43,797
Interest paid	(1,612,673)	(1,000,096)
Income tax paid	(63,500)
Net cash used in operating activities	(37,329,318)	(16,912,283)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property, plant and equipment	(9,111)	(17,707)
Purchase of short-term investments		(16,537,462)
Proceeds from disposal or redemption of short-term investments		24,955
Interest income from money market fund	279,156
Net cash used in investing activities	270,045	(16,530,214)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from long term borrowings		5,000,000
Repayment of the principal portion of lease liabilities	(147,457)	(149,007)
Repayment of the interest portion of lease liabilities	(7,207)
Proceeds from new share capital	5,854,531
Issuance of Pre-Funded Warrants and Tranche Warrants classified as equity instruments	11,975,100
Issuance of Tranche Warrants classified as financial liabilities	3,465,180
Payments for transaction costs attributable to the issuance of ordinary shares	(39,002)
Net cash generated from financing activities	21,101,145	4,850,993
NET DECREASE IN CASH AND CASH EQUIVALENTS	(15,958,128)	(28,591,504)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	56,902,077	90,167,967
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$ 40,943,949	$ 61,576,463

General Information

General Information	6 Months Ended
	Jun. 30, 2023
Disclosure Of Nature Of Operations [Abstract]
General Information	1. GENERAL INFORMATION ASLAN Pharmaceuticals Limited (“ASLAN Cayman”) was incorporated in the Cayman Islands in June 2014 and is the listing vehicle for the listing on the Nasdaq Global Market sponsored with its issuance of American Depositary Shares (“ADS”) in the United States. ASLAN Cayman and its subsidiaries (collectively referred to as the "Company”) is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The Company’s portfolio is led by eblasakimab (also known as ASLAN004), a potential first-in-class human monoclonal antibody that binds to the IL-13 receptor, blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13 which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. ASLAN Pharmaceuticals Pte. Ltd. was incorporated in Singapore in April 2010 and ASLAN Pharmaceuticals Limited was incorporated in Cayman Islands in June 2014 as the listing vehicle. The Company’s ADS have been listed on the Nasdaq Global Market since May 2018. On September 14, 2022, ASLAN Cayman submitted to the Listing Qualifications Department of Nasdaq an application to transfer the listing of its American Depositary Shares ("ADSs") representing ordinary shares of the Company from the Nasdaq Global Market to the Nasdaq Capital Market. On September 27, 2022, the Company received notice from Nasdaq that its application to transfer listing of its ADSs had been approved. The transfer was effective at the opening of business on September 29, 2022. The Company continues to trade under the symbol "ASLN." The Company has financed its operations to date primarily through the issuance of common shares. The Company has incurred net losses since inception. Please refer to Note 13 for details of the Company’s current fund-raising activities. Both the reporting and functional currency of the Company is the U.S. dollar.

Approval of Financial Statement

Approval of Financial Statements	6 Months Ended
	Jun. 30, 2023
Disclosure Of Authorization To Issue Financial Statements [Abstract]
Approval of Financial Statements	2. APPROVAL OF FINANCIAL STATEMENTS The accompanying condensed consolidated financial statements were approved by the Company’s Audit Committee on August 11, 2023.

Application of New Amended and

Application of New Amended and Revised Standards and Interpretations	6 Months Ended
	Jun. 30, 2023
Disclosure of initial application of standards or interpretations [abstract]
Application of New Amended and Revised Standards and Interpretations	3. APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS a. Amendments to the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”) mandatorily effective for the current reporting period. The application of the amendments to IFRSs included in Amendments to IAS 1 and IFRS Practice Statement 2 Disclosure of accounting policies , Amendment to IAS 8 Definition of accounting estimates , IFRS 17 Insurance Contracts and Amendment to IAS 12 Deferred tax related to assets and liabilities arising from a single transaction has had no material impact on disclosures or amounts in the Company’s consolidated financial statements. b. New and revised IFRSs issued but not yet effective At the date of authorization of these financial statements, the Company has not applied the following new and revised IFRS Standards that have been issued but are not yet effective: New IFRSs Description IFRS 10 and IAS 28 (amendments) Sale or Contribution of Assets between an Investor and its Associate or Joint Venture Amendments to IAS 1 Classification of Liabilities as Current or Non-current Amendments to IAS 1 Non-current Liabilities with Covenants Amendments to IFRS 16 Lease Liability in a Sale and Leaseback The Company anticipates that the application of these amendments may have an impact on the consolidated financial statements in future periods should such transactions arise.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. Statement of compliance The condensed consolidated financial statements have been prepared in accordance with IAS 34 “ Interim Financial Reporting ”. b. Basis of preparation The condensed consolidated financial statements have been prepared on the historical cost basis except for financial instruments and long-term incentive plan payables arising from cash-settled share-based payment arrangements which are measured at fair value. c. Basis of consolidation The condensed consolidated financial statements include the financial statements of ASLAN Cayman and entities controlled by ASLAN Cayman (its subsidiaries). When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Company. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between the members of the Company are eliminated on consolidation. d. Revenue recognition Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have reached ‘proof of concept’ to business partners for ongoing global development and launch, in the ordinary course of the Company’s activities. Revenue is presented, net of goods and services tax, rebates and discounts. See Note 22 for details of the Company’s licensing agreements. The Company recognizes revenue when it has completed the out-licensing of the experimental drug to business partners, and such partners have accepted the products. Thus, the collectability of the related receivables is reasonably assured. Typically the consideration received from out-licensing may take the form of upfront payments, option payments, milestone payments, and royalty payments on licensed products. To determine revenue recognition for contracts with customers, the Company performs the following five steps: 1) Identify the contract with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the Company satisfies the performance obligations. At the inception of a contract, the Company assesses the goods or services promised within each contract to determine whether each promised good or service is distinct and identify those that are performance obligations. The Company recognises as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Upfront License Fees If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company uses judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments At the inception of each contract with customers that includes development or regulatory milestone payments (i.e., the variable consideration), the Company includes some or all amount of variable consideration in the transaction price estimated only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty related to the variable consideration is subsequently resolved. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered highly probable of being achieved until those approvals are received. Therefore, they are not included in the transaction price. At the end of each reporting period, the Company evaluates the probability of achievement of such milestone payments and any related constraints and, if necessary, adjusts the Company’s estimate of the overall transaction price. Royalties For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of the following: 1) When the subsequent sales occur, or 2) When the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of out-licensing arrangements. e. Other significant accounting policies The accounting policies applied in these condensed consolidated financial statements are the same as those applied in the Company’s consolidated financial statements as of and for the year ended December 31, 2022.

Critical Accounting Judgments a

Critical Accounting Judgments and Key Sources of Estimation Uncertainty	6 Months Ended
	Jun. 30, 2023
Disclosure Of Accounting Judgements And Estimates [Abstract]
Critical Accounting Judgments and Key Sources of Estimation Uncertainty	5. CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY In applying the Company’s accounting policies, which are described in Note 4, the directors are required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognized and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised if the revisions affect only that period or in the period of the revisions and future periods if the revisions affect both current and future periods. For the critical accounting judgments and key sources of estimation uncertainty and assumption applied in the condensed consolidated financial statements, refer to the consolidated financial statements for the year ended December 31, 2022.

Cash and Cash Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2023
Cash and cash equivalents [abstract]
Cash and Cash Equivalents	6. CASH AND CASH EQUIVALENTS December 31, June 30, 2022 2023 Cash in hand $ 256 $ 1,095 Cash in banks 26,456,482 40,942,854 Money market fund 30,445,339 — $ 56,902,077 $ 40,943,949 Cash in banks comprise cash and short-term bank deposits with an original maturity of three months. In February 2022, the Company engaged an asset management bank to obtain better returns on the Company’s cash pursuant to Company’s Investment Policy which is designed to permit the Company to earn an attractive rate and return on its investments while limiting the risk, conserve capital and maintain liquidity. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents as they were subject to an insignificant risk of changes in value. The money market fund is highly liquid and invested in quality short-term money market instruments and is readily convertible to a known amount of cash that is subject to an insignificant risk of change. The Company discloses gains arising from such investments as cash flows arising from investing activities in the cash flow statement consistently. The money market fund was liquidated on March 21, 2023 and on June 30, 2023 the Company has no holdings in any money market fund.

Trade Receivable

Trade Receivable	6 Months Ended
	Jun. 30, 2023
Trade and other receivables [abstract]
Trade Receivable	7. TRADE RECEIVABLE December 31, June 30, 2022 2023 Trade receivable $ — $ 12,000,000 Loss allowance — — $ — $ 12,000,000 The trade receivable arises from an out-licensing agreement with Zenyaku Kogyo Co., Ltd. Please refer to Note 22 for more details. The Company collected the receivables on July 20, 2023. Please refer to Note 24 for more details.

Other Assets

Other Assets	6 Months Ended
	Jun. 30, 2023
Other Assets Current And Non Current [Abstract]
Other Assets	8. OTHER ASSETS December 31, June 30, Current 2022 2023 Prepayments $ 2,942,936 $ 1,108,278 Refundable deposits 1,033,414 1,026,789 $ 3,976,350 $ 2,135,067 The prepayments are the advanced funds paid to the Company’s contract research organizations (“CROs”) for commencement of the Company’s clinical trials and related preparation work. The refundable deposits are the receivables due from the Company’s CRO upon the project completion and office deposits refundable in normal business course. All refundable deposits are current as of December 31, 2022, and June 30, 2023.

Subsidiaries and Associate

Subsidiaries and Associate	6 Months Ended
	Jun. 30, 2023
Disclosure of subsidiaries [abstract]
Subsidiaries and Associate	9. SUBSIDIARIES AND ASSOCIATE Proportion of Investor Investee Nature of Activities December 31 June 30 Subsidiaries ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % Associate ASLAN Jaguahr Therapeutics New drug research 35 % 35 %

Investment in Associate Company

Investment in Associate Company	6 Months Ended
	Jun. 30, 2023
Disclosure of associates [abstract]
Investment in Associate Company	10. INVESTMENT IN ASSOCIATE COMPANY Details of the associate: Proportion of Name Principal Activity Principal Place December 31, June 30, Jaguahr Therapeutics Pte. Ltd. New drug research and development Singapore 35 % 35 % Summarized financial information of Jaguahr Therapeutics Pte. Ltd. is set out below. The summarized financial information below represents amounts in associate company financial statements prepared in accordance with IFRS. December 31, June 30, 2022 2023 Current assets $ 54,906 $ 1,173 Current liabilities ( 30,371 ) ( 25,984 ) Equity/(Capital deficiency) $ 24,535 $ ( 24,811 ) JAGUAHR’s loss for the six months ended June 30, 2022 and 2023 were $ 892,490 and $ 49,346 and net cash outflow from operating activities were $ 548,336 and $ 53,733 respectively. The Company recognized $ 486,141 and $ 8,587 investment losses in associate for the six months ended June 30, 2022 and June 30, 2023, and the balance of investment in associate company were $ 8,587 and $ 0 as of December 31, 2022 and June 30, 2023, respectively. The Company has no legal or constructive obligation to make payments on behalf of the associate and therefore its investment in the associate is no w NIL and with no liability recognized.

Trade And Other Payables

Trade And Other Payables	6 Months Ended
	Jun. 30, 2023
Trade and other payables [abstract]
Trade and Other Payables	11. TRADE AND OTHER PAYABLES Trade payables Trade payables are the amounts billed to the Company by the vendors and suppliers for goods delivered to or services consumed by the Company in the ordinary course of business. As of December 31, 2022, and June 30, 2023, the carrying amounts of those trade payables were $ 12,784,485 and $ 6,304,936 , respectively and repayable on demand or within the pre-agreed credit terms. Other payables December 31, June 30, 2022 2023 Payables for cash-settled long-term incentive plan (Note 17) $ 234,448 $ 478,808 Payable for salaries and bonus 1,375,627 873,768 Payable for professional fee 560,578 767,368 Others 154,385 293,625 Ending balance $ 2,325,038 $ 2,413,569 Maturity analysis: On demand or within 1 year $ 2,325,038 $ 2,413,569

Borrowings

Borrowings	6 Months Ended
	Jun. 30, 2023
Borrowings [abstract]
Borrowings	12. BORROWINGS December 31, June 30, Unsecured borrowings at amortized cost Loan from government (a) $ 11,855,579 $ 11,952,656 Secured borrowings at amortized cost Other long-term borrowings (b) 25,549,385 25,906,238 Ending balance $ 37,404,964 $ 37,858,894 Maturity analysis: Current and repayable on demand or within 1 year $ 7,748,831 $ 13,382,359 Non-current and repayable more than 1 year 29,656,133 24,476,535 Total borrowings $ 37,404,964 $ 37,858,894 a. Loans from government On April 27, 2011, the Singapore Economic Development Board (EDB) awarded the Company a repayable grant (the “Grant”) not exceeding SGD 10 million to support the Company’s drug development activities over a five-year qualifying period commencing February 24, 2011 (the “Project”). The Project was successfully implemented, resulting in substantially the full amount of the Grant being disbursed to the Company. In the event any of the Company’s clinical product candidates achieve commercial approval after Phase 3 clinical trials, the Company will be required to repay the funds disbursed to the Company under the Grant plus interest of 6 %. As of December 31, 2022, and June 30, 2023, the ending balance of the EDB loan post remeasurement including accrued interest were $ 11,855,579 and $ 11,952,656 respectively. b. Other long-term borrowings Loan and Security Agreement with K2 HealthVentures LLC On July 12, 2021, ASLAN Cayman and ASLAN Pharmaceuticals (USA) Inc. as borrowers entered into a Loan, Guaranty, and Security Agreement (the “K2HV Loan Agreement”) with K2 HealthVentures LLC (“K2HV”) as administrative agent, Ankura Trust Company, LLC as collateral agent. The borrowers’ obligations under the Loan Agreement are guaranteed by ASLAN Pharmaceuticals Pte. Ltd. (“ASLAN Singapore”) and any future material subsidiaries and secured by substantially all of borrowers’, ASLAN Singapore’s and any future subsidiary guarantors’ assets, other than intellectual property. The K2HV Loan Agreement provided for up to $ 45.0 million of delayed draw term loans, consisting of (i) the first tranche of $ 20.0 million available at closing, (ii) the second and third tranches in the aggregate amount of $ 10.0 million subject to the Company’s achievement of certain clinical milestones related to farudodstat and eblasakimab and (iii) an uncommitted fourth tranche of up to $ 15.0 million. The term loans bear interest at a floating rate equal to the greater of (i) the prime rate published by Wall Street Journal plus 5.00% and (ii) 8.25 % per annum. Under the K2HV Loan Agreement, the monthly payments are interest-only until August 1, 2023 . Pursuant to an agreed Amendment noted below, this period may be extended to August 1, 2024 , upon the Company’s achievement of certain clinical milestones. Subsequent to the interest-only period, the term loans will be payable in equal monthly instalments of principal plus accrued and unpaid interest, through the maturity date which is July 1, 2025 . The Company paid the lenders a one-time $ 255,000 facility fee at closing and will be obligated to pay for an additional facility fee equal to 0.85 % of any term loans borrowed under the fourth tranche. In addition, the Company is obligated to pay a final payment fee of 6.25 % of the original principal amount of the term loans at the maturity date. The Company may elect to prepay all, but not less than all, of the term loans prior to the term loan maturity date, subject to a prepayment fee of up to 3.0 % of the then outstanding principal balance. After repayment, no term loans may be borrowed again. On July 12, 2021, the full first tranche of $ 20.0 million available at closing was drawn down. Due to the K2 Warrant described below, the fair value of the first tranche loan on July 12, 2021, was $ 19,311,676 . Subsequent to the interest-only period under the K2HV Loan Agreement, the term loans will be payable in equal monthly instalments of principal plus accrued and unpaid interest, through the maturity date which is July 1, 2025. Borrowings under the K2HV Facility are secured with a pledge of the borrowers’ equity interests in subsidiaries and collateral over all of the Company’s cash, goods, and other personal property, with the exception of (i) the Company’s registered intellectual property assets, (ii) personal property to the extent that granting of security over any such personal property would constitute a breach of or result in the termination of, or require any consent not obtained under, any license, agreement, instrument or other document evidencing or giving rise to such property, or is otherwise prohibited by any requirement of law, and (iii) the Company’s equity interests in JAGUAHR. Such pledge and collateral may be enforced only if there has been an event of default as stipulated in the loan agreement. As of June 30, 2023, the Company was in full compliance with the loan agreement and there had been no events of default. In connection with the closing of the loan facility, the Company issued a warrant to purchase ordinary shares (the “K2 Warrant”) to K2HV. The number of ordinary shares exercisable under the K2 Warrant equals (i) 2.95 % of the aggregate term loan advances made to the Company from time to time divided by (ii) the warrant price of $ 0.5257 per ordinary share (equivalent to $ 13.1425 per ADS). The K2 Warrant also includes a cashless exercise feature allowing the holder to receive shares underlying the warrant in an amount reduced by the aggregate exercise price that would have been payable upon exercise of the warrant for such shares. The K2 Warrant is exercisable until its expiration on July 12, 2031 . The total proceeds attributed to the K2 Warrant was approximately $ 688,324 based on the relative fair value as of the date of the drawdown. As the number of ADS to be issued under the cashless method will continue to vary dependent to the share price of the Company, the K2 Warrants do not meet the equity classification and are classified as liability and fair valued though profit or loss. On January 5, 2022, the Company drew down the second tranche $ 5.0 million in full of the loan facility pursuant to the K2HV Loan Agreement. The second tranche milestone was completed, and the full funds were received on February 4, 2022. As a result of the drawdown of the second tranche of the loan facility, the number of ordinary shares exercisable under the K2 Warrant increased to 1,402,891 ordinary shares (an equivalent of 56,116 ADSs), based on the 2.95 % coverage of the total drawdown facility $ 25 million, being the aggregate term loan advances at that date, divided by the warrant price of $ 0.5257 per ordinary share (an equivalent of $ 13.1425 per ADS). On June 30, 2023, the Company entered into First Amendment to the Loan, Guaranty and Security Agreement with K2HV whereby the Company could extend the interest-only period under the K2HV Loan Agreement to November 1, 2023, February 1, 2024, or August 1, 2024, dependent on the Company’s achievement of certain milestone which has not been achieved as of June 30, 2023. Therefore, the interest-only period is still remained up to August 1, 2023 as of June 30, 2023. The K2 warrant price has reduced to $ 0.1447 per ordinary shares (an equivalent of $ 3.6175 per ADS) on the same day. As of December 31, 2022 and June 30, 2023, the fair value of the K2 Warrant was revalued to $ 90,213 and $ 704,851 respectively. The fair value (gain)/loss of $( 104,001 ) and $ 614,638 for the six months ended June 30, 2022 and 2023 being recorded under Other gains and losses respectively. See Note 20 for more detail on assumptions used in the valuation of the K2 warrant. As of June 30, 2023, K2HV had no t exercised any warrants.

Equity

Equity	6 Months Ended
	Jun. 30, 2023
Equity [abstract]
Equity	13. EQUITY Ordinary shares December 31, June 30, 2022 2023 Number of ordinary shares authorized 500,000,000 1,000,000,000 Authorized par value per share US$ 0.01 US$ 0.01 Number of ordinary shares issued and fully paid 348,723,365 416,811,380 Number of equivalent ADSs issued and fully paid 13,948,935 16,672,455 Amount of share capital par value issued and fully paid $ 63,019,962 $ 63,700,842 Amount of share capital surplus issued and fully paid $ 213,098,729 $ 218,233,378 Issuance of new ADS a) Private Placement On February 24, 2023, the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with fund entities affiliated with BVF Partners L.P. (collectively, “BVF”) and the other purchasers named therein (the “Purchasers”), pursuant to which the Company agreed to sell to the Purchasers, in a private placement offering, an aggregate of 112,359,550 ordinary shares (an equivalent of 4,494,382 ADSs), which includes (i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase twenty-five ordinary shares (represented by ADSs) at a purchase price of $ 0.178 per ordinary share (or the equivalent of $ 4.45 per ADS) and (ii) $ 4.4475 per Pre-Funded Warrant (or ADS), respectively, which represented a 15 % premium to the ADSs’ ten-day volume-weighted average price (“VWAP”) (the “Private Placement”). The Private Placement closed on February 27, 2023 and the Company received gross proceeds of approximately $ 20.0 million. The Company has issued 59,957,865 ordinary shares (an equivalent of 2,398,315 ADSs) and an additional 52,401,685 ordinary shares (an equivalent of 2,096,068 ADSs) are issuable exercise of the upon Pre-Funded Warrants. As part of the Private Placement, the Purchasers also received two tranches of warrants exercisable in the aggregate for up to 11,061,823 ADSs (or Pre-Funded Warrants). The first tranche was comprised of (i) 50 % of warrants that are exercisable upon issuance and until 60 days after the public announcement of the Company’s topline data from its TREK-AD Phase 2b clinical trial investigating eblasakimab in atopic dermatitis (the “ eblasakimab announcement”) at an exercise price of $ 6.50 per ADS (the “Tranche 1A Warrants”) and (ii) 50 % of warrants that can only be exercised within 60 days after the eblasakimab announcement at an exercise price based on the higher of $ 6.50 and a 50 % discount to the ADS VWAP measured across a specified period after the eblasakimab announcement (the “Tranche 1B Warrants”). The second tranche of warrants similarly comprised (i) 50 % of warrants that are exercisable upon issuance until 60 days after the public announcement of topline interim data from the Company’s planned Phase 2 proof of concept trial investigating farudodstat (the “ farudodstat announcement”) at an exercise price of $ 8.15 per ADS (the “Tranche 2A Warrants”) and (ii) 50 % of warrants which can only be exercised within 60 days after the farudodstat announcement at an exercise price based on the higher of $ 8.15 and a 50 % discount to the ADS VWAP measured across a specified period after the farudodstat announcement (the “Tranche 2B Warrants,” and together with the Tranche 1A Warrants, Tranche 1B Warrants and Tranche 2A Warrants, the “Tranche Warrants”). The Tranche Warrants have a term of five years and include a mandatory exercise provision, subject to the satisfaction of certain pre-specified conditions. If all Tranche Warrants are fully exercised, the Company will receive an additional $ 80.0 million in gross proceeds. The Pre-Funded Warrants issued have no expiry date. As the Pre-Funded Warrants would be settled by exchange of a fixed number of 52,401,685 ordinary shares (an equivalent of 2,096,068 ADSs), for a fixed consideration of $ 5,240 , the Pre-Funded Warrants were recognized as equity instruments. The value of the Pre-Funded Warrants was approximately $ 8,262,698 based on the relative fair value as of the Initial Exercise Date (February 27, 2023) using the binomial model. If exercised, the Tranche 1A Warrants and the Tranche 2A Warrants would be settled by issuance of a fixed number of ADSs for a fixed cash consideration upon exercise of the warrants. Hence both Tranche 1A Warrants and Tranche 2A Warrants were recognized as equity instruments and the Tranche 1A Warrants and Tranche 2A Warrants were valued approximately at $ 1,539,117 and $ 2,173,285 , respectively, based on the relative fair values as of the Initial Exercise Date (February 27, 2023) using the binomial model. The exercise price of the Tranche 1B Warrants and the Tranche 2B warrants are based on the higher of the indicated minimum exercise price and a 50 % discount to the ADS VWAP measured across a specified period after the public disclosure of the Company’s topline data from the relevant clinical trial (the Phase 2B trial for eblasakimab in the case of Tranche 1B; and the Phase 2A trial for farudodstat in the case of Tranche 2B). The variable exercise price does not meet the fixed-for-fixed criteria and hence the Tranche 1B Warrants and Tranche 2B Warrants are recognized as financial liabilities. The Tranche 1B Warrants and Tranche 2B Warrants were valued at approximately $ 1,539,897 and $ 1,925,283 , respectively, based on the relative fair values as of the date of issue (February 27, 2023) using the Monte Carlo model. As of June 30, 2023, the fair value of the Tranche 1B Warrants and Tranche 2B Warrants were revalued to $ 14,758 and $ 1,469,800 respectively. The fair value valuation gain of $ 1,980,622 was recognized in the six months ended June 30, 2023, and was recorded under Other gains and losses. See Note 20 for more detail on assumptions used in the valuation of the Tranche 1B Warrants and Tranche 2B Warrants. As of June 30, 2023, BVF and the other Purchasers had no t exercised any warrants. b) At the market (“ATM”) sale agreement On October 9, 2020, the Company entered into an Open Market Sale Agreement as amended on September 13, 2022 (the ATM Sale Agreement), with Jefferies LLC, pursuant to which we may issue and sell ADSs from time to time, through at-the-market offerings under which Jefferies LLC will act as sales agent and/or principal. During the period ended June 30, 2023, the Company had raised net proceeds of approximately $ 1.2 million under the ATM Sale Agreement by offering 8,130,150 ordinary shares (an equivalent of 325,206 ADSs). Issuance of ordinary shares to the depositary All of the Company’s outstanding ordinary shares 416,811,380 are fully paid and non-assessable. Additionally, as of June 30, 2023, the Company has issued 170,263,320 ordinary shares (an equivalent of 6,810,533 ADSs) to the depository JPMorgan Chase Bank N.A for future sales and issuance under the ATM sales agreement and 18,910,875 ordinary shares (an equivalent of 756,435 ADSs) for employee options future exercise under its employee share option plan.

Loss Before Income Tax

Loss Before Income Tax	6 Months Ended
	Jun. 30, 2023
Profit (loss) [abstract]
Loss Before Income Tax	14. LOSS BEFORE INCOME TAX a. General and administrative expenses For the six months ended June 30 2022 2023 General and administrative expenses $ 4,855,050 $ 6,814,831 General and administrative expenses primarily related to expenses of employees other than those involved in research and development and professional fees. There were no changes in the nature of general and administrative expenses. b. Research and development expenses For the six months ended June 30 2022 2023 Research and development expenses $ 19,339,045 $ 25,652,648 Research and development expenses related to preclinical and clinical development work, manufacturing and expenses of employees involved in research and development. There were no changes in the nature of research and development expense. The increase was driven by clinical development expenses and manufacturing costs related to eblasakimab and the TREK-AD Phase 2b trial, and higher headcount required in research and development work. c. Finance costs For the six months ended June 30 2022 2023 Interest on government loan $ 218,337 $ 222,357 Interest on K2HV borrowing 1,732,687 1,969,525 Interest on lease liabilities 3,741 7,207 Other interest expenses 5,556 3,252 $ 1,960,321 $ 2,202,341 d. Depreciation and amortization For the six months ended June 30 2022 2023 Right-of-use assets $ 134,402 $ 166,404 Property, plant, and equipment 8,090 12,383 Intangible assets 2,060 2,060 $ 142,552 $ 180,847 All depreciation and amortization expenses are recorded as general and administrative expenses for the six months ended June 30, 2022, and 2023. e. Employee benefits expense For the six months ended June 30 2022 2023 Short-term benefits $ 4,900,660 $ 5,477,372 Post-employment benefits 200,712 257,692 Share-based payments Equity-settled 1,336,637 1,212,832 Cash settled ( 380,964 ) 244,360 Total employee benefits expenses $ 6,057,045 $ 7,192,256 Employee benefits expenses by function General and administrative expenses $ 2,997,087 $ 3,897,264 Research and development expenses 3,059,958 3,294,992 $ 6,057,045 $ 7,192,256 f. Other gains and losses For the six months ended June 30 2022 2023 Net gain on fair value changes of financial liabilities at $ 104,001 $ 1,365,984 Net foreign exchange gain 256,084 6,102 Others ( 15,402 ) ( 20,366 ) $ 344,683 $ 1,351,720

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax [Abstract]
Income Taxes	15. INCOME TAXES Income Tax Recognized in Profit or Loss For the six months ended June 30 2022 2023 Current tax In respect of current period $ — $ 64,751 The Company has accumulated unused tax losses of $ 256 million as of June 30, 2023 (fiscal year 2022: $ 238 million) available for offset against future profits. No deferred tax asset has been recognized in respect of all the unused tax losses as it is not considered probable that there will be future taxable profits available. Subject to qualifying conditions, the unused trade losses can be carried forward indefinitely. a. Cayman Islands ASLAN Cayman is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. b. Singapore ASLAN Pharmaceuticals Pte. Ltd., incorporated in Singapore, is subject to the statutory corporate income tax rate of 17 %. ASLAN Pharmaceuticals Pte. Ltd. has no taxable income for the six months ended June 30, 2022 and 2023, and therefore, no provision for income tax is required. c. Australia ASLAN Pharmaceuticals Australia Pty Ltd., incorporated in Australia, is subject to the statutory corporate income tax of 30 %. ASLAN Pharmaceuticals Australia Pty Ltd. has no taxable income for the six months ended June 30, 2022, and 2023, and therefore, no provision for income tax is required. d. Hong Kong ASLAN Pharmaceuticals Hong Kong Limited, incorporated in Hong Kong, is subject to the statutory corporate income tax of 16.5 %. Under the Hong Kong tax law, ASLAN Pharmaceuticals Hong Kong Limited is exempted from income tax on its foreign derived income and there are no withholding taxes in Hong Kong on the remittance of dividends. ASLAN Pharmaceuticals Hong Kong Limited has no taxable income for the six months ended June 30, 2022, and 2023, and therefore, no provision for income tax is required. e. China ASLAN Pharmaceuticals (Shanghai) Co. Ltd., incorporated in China, is subject to the statutory corporate income tax rate of 25 %. ASLAN Pharmaceuticals (Shanghai) Co. Ltd. has no taxable income for the six months ended June 30, 2022, and 2023, and therefore, no provision for income tax is required. f. United States of America ASLAN Pharmaceuticals (USA) Inc., incorporated in Delaware, USA in October 2018, is subject to the statutory federal income tax rate of 21 % and state income tax rate of 8.7 %. ASLAN Pharmaceuticals (USA) Inc. has taxable income for the six months ended June 30, 2022, and therefore, total $ 70,000 tax provision for income tax was prepaid. For the six months ended June 30, 2023, ASLAN Pharmaceuticals (USA) Inc. has taxable income; therefore, total $ 64,751 tax provision for income tax was provided and $ 63,500 income tax was prepaid.

Loss Per Ordinary Share

Loss Per Ordinary Share	6 Months Ended
	Jun. 30, 2023
Earnings per share [abstract]
Loss Per Ordinary Share	16. LOSS PER ORDINARY SHARE For the six months ended June 30 2022 2023 Basic and diluted loss per ordinary share $ ( 0.07 ) $ ( 0.05 ) Basic and diluted loss per equivalent ADS $ ( 1.86 ) $ ( 1.34 ) The loss and weighted-average number of ordinary shares outstanding used in the computation of loss per share are as follows: For the six months ended June 30 2022 2023 Loss used in the computation of basic and diluted loss per share $ ( 25,971,668 ) $ ( 20,997,846 ) Weighted-average number of ordinary shares in the computation of basic loss 348,723,365 391,014,637 Weighted-average number of ADS in the computation of basic loss per ADS 13,948,935 15,640,585

Share-Based Payment Arrangement

Share-Based Payment Arrangements	6 Months Ended
	Jun. 30, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-Based Payment Arrangements	17. SHARE-BASED PAYMENT ARRANGEMENTS Employee Share Option Plan 2014 Plan Under the Company’s 2014 employee share option plan (the “2014 Plan”), qualified employees of the Company and its subsidiaries were granted 6,670,356 options (representing 13,340,712 ordinary shares, an equivalent of 533,629 ADSs) from July 2010 to July 2016. The vesting period was four years . If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest. Options pursuant to the 2014 plan are all vested in full or forfeited as of June 30, 2023. Information on employee share options granted from the 2014 Plan is as follows. Each option entitled the holder to subscribe for two ordinary shares of the Company. Below information is presented in the form of equivalent ADS (one ADS represents 25 ordinary shares): For the six months ended June 30 2022 2023 Number of Weighted- Number of Weighted- Balance at January 1 487,829 $ 17.88 371,569 $ 22.00 Equivalent ADSs expired ( 116,260 ) $ 17.08 ( 48,800 ) $ 17.08 Balance at June 30 371,569 $ 22.00 322,769 $ 22.74 Equivalent ADSs exercisable, end of period 371,569 $ 22.00 322,769 $ 22.74 2017 Plan Under the Company’s 2017 employee share option plan (the “2017 Plan”), qualified employees of the Company and its subsidiaries were granted 825,833 options (representing 825,833 ordinary shares, an equivalent of 33,033 ADSs) in September 2017. The vesting period was two years . If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest. Options granted pursuant to the 2017 Plan are all either vested in full or forfeited as of June 30, 2023. Information on employee share options granted from the 2017 Plan is as follows. Each option entitled the holder to subscribe for one ordinary share of the Company. Below information is presented in the form of equivalent ADS (one ADS represents 25 ordinary shares): For the six months ended June 30 2022 2023 Number of Weighted- Number of Weighted- Balance at January 1 20,048 $ 31.90 20,048 $ 31.90 Equivalent ADSs forfeited — — ( 333 ) 31.90 Balance at June 30 20,048 $ 31.90 19,715 $ 31.90 Equivalent ADSs exercisable, end of period 20,048 $ 31.90 19,715 $ 31.90 2020 Equity Incentive Plan On December 10, 2020, the Board of Directors (the “Board”) of the Company approved the Company’s 2020 Equity Incentive Plan (the “2020 EIP”). The 2020 EIP, among other things, provides for the grant of restricted stock awards, stock options and other equity-based awards to employees, officers, directors and consultants. The vesting period is up to four years , unless it is determined that a different vesting schedule shall apply, in the discretion of the Administrator. If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest. Each option entitles the holder to subscribe for one ADS of the Company. The options granted are valid for 10 years. No performance conditions were attached to the plan. No more than 62,030,922 ordinary shares (an equivalent of 2,481,237 ADSs) may be issued under the 2020 EIP upon the exercise of options. In addition, the number of ordinary shares reserved for issuance under the 2020 EIP will automatically increase on January 1 of each year, commencing on January 1, 2022, and ending on (and including) January 1, 2030, in an amount equal to 4 % of the total number of ordinary shares outstanding on December 31 of the preceding calendar year. The Board may determine prior to January 1 of a given year that there will be no increase for such year or that the increase for such year will be a lesser number of ordinary shares. In connection with the approval of the 2020 EIP, the maximum number of ordinary shares that may be issued under the 2020 EIP was originally 20,676,974 ordinary shares (an equivalent of 827,079 ADSs). The Board determined that there would be no increase as from January 1, 2021. As from January 1, 2022 and January 1, 2023, there was an options increase of 13,948,935 ordinary shares (an equivalent of 557,958 ADSs), which represents 4 % of the total outstanding ordinary shares as of December 31, 2021. As from January 1, 2023, there was an options increase of 13,948,935 ordinary shares (an equivalent of 557,958 ADSs), which represents 4 % of the total outstanding ordinary shares as of December 31, 2022. On December 15, 2020, 764,812 ADSs were granted under the Company’s 2020 EIP. During the year ended December 31, 2021, 56,400 ADSs were granted under the Company’s 2020 EIP, respectively. On January 1, 2022, and on July 1, 2022, 355,030 ADSs and 143,600 ADSs were granted, respectively. On January 1, 2023, and on May 1, 2023, 407,226 ADSs and 370,000 ADSs were granted, respectively. If an award under the 2020 EIP, expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, cancelled without having been fully exercised, forfeited or is withheld to satisfy a tax withholding obligation in connection with an award or to satisfy a purchase or exercise price of an award, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2020 EIP. Awards granted under the 2020 EIP in substitution for any options or other equity or equity-based awards granted by an entity before the entity’s merger or consolidation with the Company or the Company’s acquisition of the entity’s property or stock will not reduce the number of ordinary shares available for grant under the 2020 EIP, but will count against the maximum number of ordinary shares that may be issued upon the exercise of incentive stock options. References in this summary to ordinary shares include an equivalent number of the Company’s ADSs. In July 2022, the Remuneration Committee of the Board noted that the exercise price of options previously granted to certain officers and employees of the Company significantly exceeded the current fair market value of the underlying ADS (the “Underwater Options”). In accordance with its powers authorized under the 2020 EIP, the Remuneration Committee therefore resolved to lower the per ADS exercise price of the Underwater Options, believing this to be in the best interests of the Company and its shareholders to motivate and restore incentives for the holders of the Underwater Options. It thus resolved to amend each Underwater Option to reduce the exercise price of each to $ 2.60 per ADS for the 2020 EIP, being the Fair Market Value of the Company’s ADSs effective on the closest trading day to the date of the resolution. The incremental fair value of $ 279,636 will be recognized as an expense over the period from the modification date to the end of vesting period. The expense for the original option grant will be recognized as if the terms had not been modified. The fair value of the modified options was determined using the same models and principles as described above. Information on employee share options granted under the 2020 EIP is as follows. Each option entitles the holder to subscribe for one ADS of the Company: For the six months ended June 30 2022 2023 Number of Weighted- Number of Weighted- Balance at January 1 804,313 $ 10.30 1,154,072 $ 2.59 Equivalent ADSs granted 355,030 $ 5.60 777,226 $ 2.92 Equivalent ADSs forfeited ( 148,875 ) $ 10.30 — $ — Balance at June 30 1,010,468 $ 8.65 1,931,298 $ 2.72 Equivalent ADS exercisable, end of period 241,205 $ 8.65 673,880 $ 2.59 Information on outstanding options as of June 30, 2023 is as follows: July July July July December January - July January July January May Range of ADS Exercise Price $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.60 $ 2.50 $ 1.80 $ 4.15 Weighted-average Remaining Contractual 1.0 2.0 3.0 4.24 7.46 7.71 8.51 9.01 9.52 9.84 July July July July December January - July January July January May Grant-date ADS share price $ 6.80 $ 9.40 $ 11.30 $ 6.40 $ 11.10 $ 11.75 $ 5.60 $ 2.50 $ 1.80 $ 4.15 ADS Exercise price $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.60 $ 2.50 $ 1.80 $ 4.15 Expected volatility 50.86 % 36.37 % 39.34 % 38.33 % 66.25 % 118.1 % 122.1 % 118.2 % 133.5 % 130.5 % Expected life (years) 10 10 10 10 5.25 - 7 5.25 - 7 5.25 - 7 5.25 - 7 5.5 - 7 5.5 - 7 Risk-free interest rate 2.58 % 2.43 % 1.46 % 1.10 % 3.06 % 3.06 % 3.06 % 2.91 % 3.92 % 3.58 % Expected volatility was based on the average annualized historical share price volatility of comparable companies before the grant date. Compensation costs recognized for the six months ended June 30, 2022, and June 30, 2023, were $ 1,336,637 and $ 1,212,832 , respectively. Long Term Incentive Plan The Company maintains the Senior Management Team (SMT) Long Term Incentive Plans (LTIP), pursuant to which bonus entitlement unit awards were granted in 2017, 2018, and 2019. On August 23, 2017, and February 1, 2018, the Company granted 1,462,000 and 104,000 ordinary shares (equivalent to 58,480 ADSs and 4,160 ADSs) bonus entitlement units to the Company’s executive officers pursuant to the 2017 LTIP, respectively. On July 30, 2018, the Company granted 48,228 ADSs bonus entitlement units to the executive officers pursuant to the 2018 LTIP, and on July 30, 2019, the Company granted 98,204 ADSs bonus entitlement units to the executive officers pursuant to the 2019 LTIP. Upon vesting and redemption, each unit award is converted into a cash payment equal to the number of units multiplied by the per-share fair market value of the Company’s ordinary shares on the day following the Company’s receipt of a redemption notice. The bonus entitlement unit awards granted pursuant to the 2017 LTIP, the 2018 LTIP and the 2019 LTIP are all either vested in full or forfeited as of June 30, 2023. Up to date, total 56,700 ADSs bonus entitlement units have been forfeited and total 42,123 ADSs bonus entitlement units have been redeemed as of June 30, 2023. As of June 30, 2023, the balance of ADSs bonus entitlement units under LTIP schemes were 110,249 and the quoted fair value on the reporting date is based on the closing price per ADS $ 3.65 . The LTIPs qualify as cash-settled share-based payment transactions. The Company recognizes the liabilities in respect of its obligations under the LTIPs, which are measured based on the Company’s quoted market price of its ADSs at the reporting date, and takes into account the extent to which the services have been rendered to date. The Company recognized a total benefit of $ 380,964 and a total expense of $ 244,360 in respect of the LTIPs for the six months ended June 30, 2022, and 2023, respectively. As of December 31, 2022, and June 30, 2023, the Company recognized compensation liabilities of $ 234,448 and $ 478,808 as current (classified as other payables), respectively. The Company’s LTIP is described as follows: For the six months ended June 30 Number of ADSs 2022 2023 Balance at January 1 144,146 144,146 Awards exercised — ( 20,000 ) Awards elapsed — ( 13,897 ) Balance at June 30 144,146 110,249 Balance exercisable, end of period 118,349 110,249

Capital Management

Capital Management	6 Months Ended
	Jun. 30, 2023
Disclosure Of Capital Management [Abstract]
Capital Management	18. CAPITAL MANAGEMENT The Company manages its capital to ensure that entities in the Company will be able to safeguard cash as well as maintain financial liquidity and flexibility to support the development of its product candidates and programs as a going concern through the optimization of the debt and equity balance. The Company’s financial strategy is designed to maintain a flexible capital structure consistent with the objectives stated above and to respond to business growth opportunities and changes in economic conditions. The capital structure of the Company mainly consists of borrowings and equity of the Company. Key management personnel of the Company review the capital structure periodically. To maintain or balance the overall capital structure, the Company may adjust the amounts of long-term borrowings, or the issuance of new shares capital or other equity instruments. As of June 30, 2023, there were no changes in the Company’s capital management policy, and the Company was not subject to any externally imposed capital requirements other than those restrictions disclosed in Note 12 under K2HV Loan Agreement.

Reconciliation of Liabilities A

Reconciliation of Liabilities Arising from Financing Activities	6 Months Ended
	Jun. 30, 2023
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Reconciliation of Liabilities Arising from Financing Activities	19. RECONCILIATION OF LIABILITIES ARISING FROM FINANCING ACTIVITIES The table below details changes in the Company’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Company’s consolidated statements of cash flows as cash flows from financing activities. Non-cash changes January 1, Interest Net Additions/ Others* Interest June 30, Lease Liabilities – current $ 199,124 ( 3,741 ) ( 149,007 ) — — 3,741 $ 50,117 Long-term borrowings (Note 12) $ 30,857,308 — 5,000,000 ( 1,044,027 ) ( 344,266 ) 1,951,024 $ 36,420,039 Interest payables (Note 11) $ 142,083 ( 996,355 ) — 1,044,027 — 5,556 $ 195,313 Non-cash changes January 1, Interest Net Additions/ Others* Interest June 30, Lease Liabilities – current $ 215,671 ( 7,207 ) ( 147,457 ) — — 7,207 $ 68,214 Long-term borrowings (Note 12) $ 29,656,133 ( 1,612,673 ) — ( 5,633,528 ) ( 125,279 ) 2,191,882 $ 24,476,535 Current borrowings (Note 12) $ 7,748,831 — — 5,633,528 — — $ 13,382,359 Financial liabilities at fair value through profit or loss**** $ 90,213 — 3,465,180 — ( 1,365,984 ) — $ 2,189,409 * Others comprise mainly foreign currency translation differences for long-term borrowings and net gain on fair value changes for financial liabilities measured at fair value through profit or loss. ** Transfer from long-term borrowings represented reclassified the current portion of the long-term borrowing to current borrowing. *** The Company classified interest paid arising from leases into financing cash flows activities and interest paid to non-related parties arising from borrowings into operating cash flows activities which is under the Company’s accounting policy which is consistently applied. **** Net proceeds arising from financial liabilities at fair value through profit or loss represented transfer of fair value for warrants at inception.

Financial Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	20. FINANCIAL INSTRUMENTS a. Fair value of financial instruments not measured at fair value The Company believes that the carrying amounts of financial assets and financial liabilities not measured at fair value approximate their fair values. b. Fair value of financial instruments measured at fair value on a recurring basis 1) Fair value hierarchy December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets at fair value through profit or loss Money Market Fund $ 30,445,339 $ — $ — $ 30,445,339 Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants $ — $ — $ 90,213 $ 90,213 June 30, 2023 Level 1 Level 2 Level 3 Total Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants $ — $ — $ 704,851 $ 704,851 Derivative financial liabilities – Tranche 1B Warrants $ — $ — $ 14,758 $ 14,758 Derivative financial liabilities – Tranche 2B Warrants $ — $ — $ 1,469,800 $ 1,469,800 Total $ — $ — $ 2,189,409 $ 2,189,409 The following three levels of inputs are used to measure the fair value presented above: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. There was no transfer between Levels 1, 2 and 3 in the current and prior periods. 2) Valuation techniques and inputs applied for Level 3 fair value measurement The fair values of warrants are determined using option pricing models where the significant unobservable input is historical volatility. An increase in the historical volatility used in isolation would result in an increase in the fair value. Valuation Methodology Remaining Contractual Life (years) Historical Volatility December 31, 2022 June 30, 2023 December 31, 2022 June 30, 2023 Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants Binomial Tree 8.53 8.03 132.9 % 128.6 % Derivative financial liabilities – Tranche 1B Warrants Monte Carlo — 0.18 — 57.5 % Derivative financial liabilities – Tranche 2B Warrants Monte Carlo — 1.08 - 1.67 — 83.4 % - 91.3 % c. Categories of financial instruments December 31, June 30, 2022 2023 Financial assets Financial assets at fair value through profit or loss Money market fund $ 30,445,339 $ — Financial assets at amortized cost (1) $ 27,490,152 $ 53,970,737 Financial liabilities Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants $ 90,213 $ 704,851 Derivative financial liabilities – Tranche 1B Warrants $ — $ 14,758 Derivative financial liabilities – Tranche 2B Warrants $ — $ 1,469,800 $ 90,213 $ 2,189,409 Financial liabilities at amortized cost (2) $ 41,922,924 $ 46,098,591 Equity instruments Equity instruments Pre-Funded Warrants $ — $ 8,262,698 Tranche 1A Warrants $ — $ 1,539,117 Tranche 2A Warrants $ — $ 2,173,285 $ — $ 11,975,100 1) The balances include financial assets at amortized cost, which comprise of cash and cash equivalents, trade receivable and refundable deposits. 2) The balances include financial liabilities at amortized cost, which comprise of trade payables, partial other payables, other current liabilities and long-term borrowings. d. Financial risk management objectives and policies The Company’s financial risk management objective is to monitor and manage the financial risks relating to the operations of the Company. These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. To minimize the effect of financial risks, the Company devoted time and resources to identify and evaluate the uncertainty of the market to mitigate risk exposures. 1) Market risk The Company’s activities exposed it primarily to the financial risks of changes in foreign currency exchange rates (see (a) below) and interest rates (see (b) below). a) Foreign currency risk The Company had foreign currency transactions, which exposed the Company to foreign currency risk. The Company’s significant financial assets and liabilities denominated in foreign currencies were as follows: December 31, 2022 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 2,312,357 0.7461 $ 1,725,279 AUD A $ 2,616,802 0.6820 $ 1,784,606 Financial liabilities Monetary items SGD S $ 16,298,191 0.7461 $ 12,160,288 June 30, 2023 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 1,707,639 0.7329 $ 1,251,462 AUD A $ 1,463,565 0.6642 $ 972,042 Financial liabilities Monetary items SGD S $ 16,649,298 0.7329 $ 12,201,621 Sensitivity analysis The Company is mainly exposed to the Singapore Dollar. The following table details the Company’s sensitivity to a 5 % decrease in the U.S. dollar against the relevant foreign currency. The rate of 5 % is the sensitivity rate used when reporting foreign currency risk internally to key management personnel and represents management’s assessment of the reasonably possible change in foreign exchange rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items. A negative number below indicates an increase in pre-tax loss where the U.S. dollar weakens 5 % against the relevant currency. For a 5 % strengthening of the U.S. dollar against the relevant currency, there would be an equal and opposite impact on pre-tax loss. For the six months ended June 30 2022 2023 Profit or loss* SGD $ ( 499,773 ) $ ( 547,508 ) AUD $ — $ 41,451 * This is mainly attributable to the exposure to outstanding deposits in banks and loans in foreign currency at the end of the reporting period. b) Interest rate risk The Company is exposed to interest rate risk because entities in the Company borrowed funds at fixed baseline interest plus floating interest rates. The sensitivity analysis below is determined based on the Company’s exposure to interest rates for fixed rate borrowings at the end of the reporting period and is prepared assuming that the amounts of liabilities outstanding at the end of the reporting period are outstanding for the whole year. A 100 -basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management’s assessment of the reasonably possible change in interest rates. If interest rates had been 100 basis points higher and all other variables were held constant, the Company’s pre-tax loss for the six months ended June 30, 2022, and 2023 would have increased by $ 364,200 and $ 378,589 , respectively. 2) Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Company. The Company adopted a policy of only dealing with creditworthy counterparties and financial institutions, where appropriate, as a means of mitigating the risk of financial loss from defaults. 3) Liquidity risk The Company manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents that are deemed adequate to finance the Company’s operations and mitigate the effects of fluctuations in cash flows. In addition, management monitors the utilization of long-term borrowings and ensures compliance with repayment conditions. As the Company is in the research and development phase, the Company will be seeking future funding based on the requirements of its business operations. The Company is able to exercise discretion and flexibility to deploy its capital resources in the process of the research and development activities according to the schedule of fund raising. The Company intends to explore various means of fundraising to meet its funding requirements to carry out the business operations, such as the issuance of its ordinary shares sponsoring ADS. The Company may also use other means of financing such as out licensing to generate revenue and cash. Management believes that it currently has plans and opportunities in place which will allow it to fund and meet its operating expenses and capital expenditure requirements and meet its obligations for at least the next twelve months from June 30, 2023. On February 24, 2023, the Company entered into a Unit Purchase Agreement (the “Purchase Agreement”) with fund entities affiliated with BVF Partners L.P. (collectively, “BVF”) private placement. The Private Placement became effective on February 27, 2023 (the “Closing”), subject to customary closing conditions. The Company received gross proceeds of $ 20.0 million from the Private Placement, and is expected to raise an additional $ 80.0 million in gross proceeds to the Company if all Tranche Warrants are fully-exercised. Please refer to Note 13 for details.

Transactions with Related Parti

Transactions with Related Parties	6 Months Ended
	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
Transactions with Related Parties	21. TRANSACTIONS WITH RELATED PARTIES Balances and transactions between the companies which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Besides information disclosed elsewhere in the other notes, details of transactions between the Company and other related parties are disclosed as follows. a. Related party name and category Related Party Name Related Party Category Others Key Management Personnel b. Compensation of Key Management Personnel For the six months ended June 30 2022 2023 Short-term employee benefits $ 1,102,592 $ 1,180,189 Post-employment benefits 242,554 72,292 Share-based payments recognized 602,988 952,388 $ 1,948,134 $ 2,204,869 The remuneration of directors and key executives was determined by the Remuneration Committee based on the performance of individuals and market trends. In addition, the remunerations of non-executive directors were $ 116,833 and $ 143,000 for the six months ended June 30, 2022 and 2023, respectively.

Material License Agreements

Material License Agreements	6 Months Ended
	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
Material License Agreements	22. MATERIAL LICENSE AGREEMENTS Almirall In 2012, the Company originally entered into a global licensing agreement with Almirall to develop DHODH inhibitor, LAS186323, which the Company refers to as farudodstat , for rheumatoid arthritis (excluding any topical formulation), without upfront payments. Under the license agreement, the Company agreed to fund and develop farudodstat to the end of Phase 2 through a development program. The original license agreement was replaced by a new agreement, executed in December 2015 and amended in March 2018 , granting an exclusive, worldwide license to develop, manufacture and commercialize farudodstat products for all human diseases, excluding topically-administered products embodying the compound for keratinocyte and hyperproliferative disorders, and the non-melanoma skin cancers basal cell carcinoma, squamous cell carcinomas and Gorlin Syndrome. Under the license agreement, Almirall is eligible to receive milestone payments and royalties based on the sales generated by the Company and/or sublicensees. As of June 30, 2023, the Company did not accrue for the above contingent payments since the milestones have not yet been achieved. CSL The Company entered into a global license agreement with CSL Limited (“CSL”), in May 2014, to develop the anti-IL13 receptor monoclonal antibody, CSL334 (which the Company refers to as eblasakimab ) and antigen binding fragments thereof, for the treatment, diagnosis or prevention of diseases or conditions in humans, without upfront payments. This license agreement was amended in May 31, 2019, pursuant to which the Company obtained an exclusive, worldwide license to certain intellectual property owned or licensed by CSL, including patents and know-how, to develop, manufacture for clinical trials and commercialize eblasakimab for the treatment, diagnosis or prevention of diseases or conditions in humans. The Company’s development under such agreement is currently focused on the treatment of respiratory and inflammatory conditions, and in particular, atopic dermatitis. Under the amended agreement, the Company is generally obligated to use diligent efforts to develop eblasakimab products in accordance with the development plan, to obtain marketing approvals for eblasakimab products worldwide and to commercialize eblasakimab products, either by itself or through sublicensees. In consideration of the rights granted to the Company under the amended agreement, the Company will make a first payment of $ 30 million to CSL upon commencement of a Phase 3 clinical trial of eblasakimab . The Company will also be required to pay up to an aggregate of $ 95 million to CSL if certain regulatory milestones are achieved, up to an aggregate of $ 655 million if certain sales milestones are achieved and tiered royalties on net sales of eblasakimab products ranging between a mid-single digit percentage and 10 %. The Company is also responsible for all payments to third-party licensors to CSL, to the extent such obligations relate to the exploitation of the rights licensed under CSL’s agreement with those parties and sublicensed to the Company under the amended agreement. As of June 30, 2023, the Phase 2b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis is still ongoing and the aforementioned milestones have not been met. The Company did not make any other payments related to the in-license agreements for the six months ended June 30, 2022, and 2023. Zenyaku Kogyo Co., ltd In June 2023, the Company entered into a development and commercialization agreement with Zenyaku Kogyo Co., Ltd. (“Zenyaku”) granting to Zenyaku the exclusive rights to develop and, provided certain conditions are met, commercialize eblasakimab in atopic dermatitis and all other indications in Japan. Zenyaku agreed to make a non-refundable upfront payment of $ 12 million in return for the use of the rights granted to Zenyaku. In addition, the Company is eligible to receive up to $ 29.5 million in development milestones and up to $ 94 million in commercial milestones. Zenyaku will make double digit royalty payments to ASLAN on net sales of eblasakimab in percentages ranging up to low twenties. Under the terms of the agreement, Zenyaku will be exclusively responsible for all development and, potentially, commercialization activities for eblasakimab in Japan. Zenyaku plans to initiate a Phase 1 study of eblasakimab in Japan in the first half of 2024. The Company does not bear any risks and costs on the development of eblasakimab by Zenyaku in Japan. Accordingly, Zenyaku has exclusive control over relevant activities that significantly affect the returns of the development and commercialization of eblasakimab in Japan. Since the Company has no other performance obligation in addition to the agreement, the Company recognized the upfront payments of $ 12 million as revenue in the period of June 30, 2023.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2023
Disclosure of operating segments [abstract]
Segment Reporting	23. SEGMENTAL REPORTING The company’s major business is research and development and operates only in one single segment. The Board of Directors, who allocates resources and assesses performance of the Company as a whole, has identified that the Company has only one reportable operating segment. The Company has only one reportable operating segment, and therefore, the reportable segment information is the same as the financial statements. The following is an analysis of the Company’s revenue from its major products and services. For the six months ended June 30 2022 2023 Out-licensing $ — $ 12,000,000 For the period ended June 30, 2023, there was revenue generated from out-licensing of development and commercialization rights in Japan to Zenyaku Kogyo Co., Ltd. for eblasakimab amounting to $ 12 million.

Other Items_Subsequent Events

Other Items/Subsequent Events	6 Months Ended
	Jun. 30, 2023
Disclosure of non-adjusting events after reporting period [abstract]
Other Items/Subsequent Events	24. OTHER ITEMS/SUBSEQUENT EVENTS a) On July 6, 2023, the Company announced positive topline data from its Phase 2b dose-ranging study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis, the TREK-AD (Trials with EblasaKimab in Atopic Dermatitis) Study. b) On July 20, 2023, the Company received $ 12,000,000 from Zenyaku being the upfront payment pursuant to the strategic licensing agreement referred to in Note 22 above.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2023
Disclosure Of Significant Accounting Policies [Abstract]
Statement of compliance	a. Statement of compliance The condensed consolidated financial statements have been prepared in accordance with IAS 34 “ Interim Financial Reporting ”.
Basis of preparation	b. Basis of preparation The condensed consolidated financial statements have been prepared on the historical cost basis except for financial instruments and long-term incentive plan payables arising from cash-settled share-based payment arrangements which are measured at fair value.
Basis of consolidation	c. Basis of consolidation The condensed consolidated financial statements include the financial statements of ASLAN Cayman and entities controlled by ASLAN Cayman (its subsidiaries). When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by the Company. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between the members of the Company are eliminated on consolidation.
Revenue recognition	d. Revenue recognition Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have reached ‘proof of concept’ to business partners for ongoing global development and launch, in the ordinary course of the Company’s activities. Revenue is presented, net of goods and services tax, rebates and discounts. See Note 22 for details of the Company’s licensing agreements. The Company recognizes revenue when it has completed the out-licensing of the experimental drug to business partners, and such partners have accepted the products. Thus, the collectability of the related receivables is reasonably assured. Typically the consideration received from out-licensing may take the form of upfront payments, option payments, milestone payments, and royalty payments on licensed products. To determine revenue recognition for contracts with customers, the Company performs the following five steps: 1) Identify the contract with a customer; 2) Identify the performance obligations in the contract; 3) Determine the transaction price; 4) Allocate the transaction price to the performance obligations in the contract; and 5) Recognize revenue when (or as) the Company satisfies the performance obligations. At the inception of a contract, the Company assesses the goods or services promised within each contract to determine whether each promised good or service is distinct and identify those that are performance obligations. The Company recognises as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Upfront License Fees If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other performance obligations, the Company uses judgment to assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments At the inception of each contract with customers that includes development or regulatory milestone payments (i.e., the variable consideration), the Company includes some or all amount of variable consideration in the transaction price estimated only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty related to the variable consideration is subsequently resolved. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered highly probable of being achieved until those approvals are received. Therefore, they are not included in the transaction price. At the end of each reporting period, the Company evaluates the probability of achievement of such milestone payments and any related constraints and, if necessary, adjusts the Company’s estimate of the overall transaction price. Royalties For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of the following: 1) When the subsequent sales occur, or 2) When the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of out-licensing arrangements.
Other significant accounting policies	e. Other significant accounting policies The accounting policies applied in these condensed consolidated financial statements are the same as those applied in the Company’s consolidated financial statements as of and for the year ended December 31, 2022.

Application of New Amended an_2

Application of New Amended and Revised Standards and Interpretations (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of initial application of standards or interpretations [abstract]
Schedule of New Amended or Revised Standards and Interpretations	At the date of authorization of these financial statements, the Company has not applied the following new and revised IFRS Standards that have been issued but are not yet effective: New IFRSs Description IFRS 10 and IAS 28 (amendments) Sale or Contribution of Assets between an Investor and its Associate or Joint Venture Amendments to IAS 1 Classification of Liabilities as Current or Non-current Amendments to IAS 1 Non-current Liabilities with Covenants Amendments to IFRS 16 Lease Liability in a Sale and Leaseback

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	6 Months Ended
	Jun. 30, 2023
Cash and cash equivalents [abstract]
Summary of Cash and Cash Equivalents	December 31, June 30, 2022 2023 Cash in hand $ 256 $ 1,095 Cash in banks 26,456,482 40,942,854 Money market fund 30,445,339 — $ 56,902,077 $ 40,943,949

Trade Receivable (Tables)

Trade Receivable (Tables)	6 Months Ended
	Jun. 30, 2023
Trade and other current receivables [abstract]
Summary of Trade Receivable	December 31, June 30, 2022 2023 Trade receivable $ — $ 12,000,000 Loss allowance — — $ — $ 12,000,000

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Jun. 30, 2023
Other Assets Current And Non Current [Abstract]
Summary of Other Assets	December 31, June 30, Current 2022 2023 Prepayments $ 2,942,936 $ 1,108,278 Refundable deposits 1,033,414 1,026,789 $ 3,976,350 $ 2,135,067

Subsidiaries and Associate (Tab

Subsidiaries and Associate (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of subsidiaries [abstract]
Summary of Subsidiaries and Associate Included in Consolidated Financial Statements	Proportion of Investor Investee Nature of Activities December 31 June 30 Subsidiaries ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % ASLAN ASLAN New drug research 100 % 100 % Associate ASLAN Jaguahr Therapeutics New drug research 35 % 35 %

Investment in Associate Compa_2

Investment in Associate Company (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of associates [abstract]
Summary of Subsidiaries That Have Material Non-controlling Interests	Details of the associate: Proportion of Name Principal Activity Principal Place December 31, June 30, Jaguahr Therapeutics Pte. Ltd. New drug research and development Singapore 35 % 35 %
Summary of Financial Information Before Intragroup Eliminations	Summarized financial information of Jaguahr Therapeutics Pte. Ltd. is set out below. The summarized financial information below represents amounts in associate company financial statements prepared in accordance with IFRS. December 31, June 30, 2022 2023 Current assets $ 54,906 $ 1,173 Current liabilities ( 30,371 ) ( 25,984 ) Equity/(Capital deficiency) $ 24,535 $ ( 24,811 )

Trade And Other Payables (Table

Trade And Other Payables (Tables)	6 Months Ended
	Jun. 30, 2023
Trade and other payables [abstract]
Schedule of Other Payables	Other payables December 31, June 30, 2022 2023 Payables for cash-settled long-term incentive plan (Note 17) $ 234,448 $ 478,808 Payable for salaries and bonus 1,375,627 873,768 Payable for professional fee 560,578 767,368 Others 154,385 293,625 Ending balance $ 2,325,038 $ 2,413,569 Maturity analysis: On demand or within 1 year $ 2,325,038 $ 2,413,569

Borrowings (Tables)

Borrowings (Tables)	6 Months Ended
	Jun. 30, 2023
Borrowings [abstract]
Summary of Loans	December 31, June 30, Unsecured borrowings at amortized cost Loan from government (a) $ 11,855,579 $ 11,952,656 Secured borrowings at amortized cost Other long-term borrowings (b) 25,549,385 25,906,238 Ending balance $ 37,404,964 $ 37,858,894 Maturity analysis: Current and repayable on demand or within 1 year $ 7,748,831 $ 13,382,359 Non-current and repayable more than 1 year 29,656,133 24,476,535 Total borrowings $ 37,404,964 $ 37,858,894

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [abstract]
Schedule of Ordinary Shares	Ordinary shares December 31, June 30, 2022 2023 Number of ordinary shares authorized 500,000,000 1,000,000,000 Authorized par value per share US$ 0.01 US$ 0.01 Number of ordinary shares issued and fully paid 348,723,365 416,811,380 Number of equivalent ADSs issued and fully paid 13,948,935 16,672,455 Amount of share capital par value issued and fully paid $ 63,019,962 $ 63,700,842 Amount of share capital surplus issued and fully paid $ 213,098,729 $ 218,233,378

Loss Before Income Tax (Tables)

Loss Before Income Tax (Tables)	6 Months Ended
	Jun. 30, 2023
Profit (loss) [abstract]
Schedule of General and Administrative Expenses	a. General and administrative expenses For the six months ended June 30 2022 2023 General and administrative expenses $ 4,855,050 $ 6,814,831 General and administrative expenses primarily related to expenses of employees other than those involved in research and development and professional fees. There were no changes in the nature of general and administrative expenses.
Schedule of Research and Development Expenses	b. Research and development expenses For the six months ended June 30 2022 2023 Research and development expenses $ 19,339,045 $ 25,652,648 Research and development expenses related to preclinical and clinical development work, manufacturing and expenses of employees involved in research and development. There were no changes in the nature of research and development expense. The increase was driven by clinical development expenses and manufacturing costs related to eblasakimab and the TREK-AD Phase 2b trial, and higher headcount required in research and development work.
Summary of Finance costs	c. Finance costs For the six months ended June 30 2022 2023 Interest on government loan $ 218,337 $ 222,357 Interest on K2HV borrowing 1,732,687 1,969,525 Interest on lease liabilities 3,741 7,207 Other interest expenses 5,556 3,252 $ 1,960,321 $ 2,202,341
Schedule of Depreciation and Amortization	d. Depreciation and amortization For the six months ended June 30 2022 2023 Right-of-use assets $ 134,402 $ 166,404 Property, plant, and equipment 8,090 12,383 Intangible assets 2,060 2,060 $ 142,552 $ 180,847 All depreciation and amortization expenses are recorded as general and administrative expenses for the six months ended June 30, 2022, and 2023.
Schedule of Employee Benefits Expense	e. Employee benefits expense For the six months ended June 30 2022 2023 Short-term benefits $ 4,900,660 $ 5,477,372 Post-employment benefits 200,712 257,692 Share-based payments Equity-settled 1,336,637 1,212,832 Cash settled ( 380,964 ) 244,360 Total employee benefits expenses $ 6,057,045 $ 7,192,256 Employee benefits expenses by function General and administrative expenses $ 2,997,087 $ 3,897,264 Research and development expenses 3,059,958 3,294,992 $ 6,057,045 $ 7,192,256
Schedule of Other Gains and Losses	f. Other gains and losses For the six months ended June 30 2022 2023 Net gain on fair value changes of financial liabilities at $ 104,001 $ 1,365,984 Net foreign exchange gain 256,084 6,102 Others ( 15,402 ) ( 20,366 ) $ 344,683 $ 1,351,720

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jun. 30, 2023
Income Tax [Abstract]
Summary of Income Tax Recognised in Profit or Loss	Income Tax Recognized in Profit or Loss For the six months ended June 30 2022 2023 Current tax In respect of current period $ — $ 64,751

Loss Per Ordinary Share (Tables

Loss Per Ordinary Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings per share [abstract]
Summary of Earnings Per Share	For the six months ended June 30 2022 2023 Basic and diluted loss per ordinary share $ ( 0.07 ) $ ( 0.05 ) Basic and diluted loss per equivalent ADS $ ( 1.86 ) $ ( 1.34 )
Summary of Loss and Weighted-Average Number of Ordinary Shares Outstanding	The loss and weighted-average number of ordinary shares outstanding used in the computation of loss per share are as follows: For the six months ended June 30 2022 2023 Loss used in the computation of basic and diluted loss per share $ ( 25,971,668 ) $ ( 20,997,846 ) Weighted-average number of ordinary shares in the computation of basic loss 348,723,365 391,014,637 Weighted-average number of ADS in the computation of basic loss per ADS 13,948,935 15,640,585

Share-Based Payment Arrangeme_2

Share-Based Payment Arrangements (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Summary of Employee Share Options	Information on employee share options granted from the 2014 Plan is as follows. Each option entitled the holder to subscribe for two ordinary shares of the Company. Below information is presented in the form of equivalent ADS (one ADS represents 25 ordinary shares): For the six months ended June 30 2022 2023 Number of Weighted- Number of Weighted- Balance at January 1 487,829 $ 17.88 371,569 $ 22.00 Equivalent ADSs expired ( 116,260 ) $ 17.08 ( 48,800 ) $ 17.08 Balance at June 30 371,569 $ 22.00 322,769 $ 22.74 Equivalent ADSs exercisable, end of period 371,569 $ 22.00 322,769 $ 22.74 Information on employee share options granted from the 2017 Plan is as follows. Each option entitled the holder to subscribe for one ordinary share of the Company. Below information is presented in the form of equivalent ADS (one ADS represents 25 ordinary shares): For the six months ended June 30 2022 2023 Number of Weighted- Number of Weighted- Balance at January 1 20,048 $ 31.90 20,048 $ 31.90 Equivalent ADSs forfeited — — ( 333 ) 31.90 Balance at June 30 20,048 $ 31.90 19,715 $ 31.90 Equivalent ADSs exercisable, end of period 20,048 $ 31.90 19,715 $ 31.90 Information on employee share options granted under the 2020 EIP is as follows. Each option entitles the holder to subscribe for one ADS of the Company: For the six months ended June 30 2022 2023 Number of Weighted- Number of Weighted- Balance at January 1 804,313 $ 10.30 1,154,072 $ 2.59 Equivalent ADSs granted 355,030 $ 5.60 777,226 $ 2.92 Equivalent ADSs forfeited ( 148,875 ) $ 10.30 — $ — Balance at June 30 1,010,468 $ 8.65 1,931,298 $ 2.72 Equivalent ADS exercisable, end of period 241,205 $ 8.65 673,880 $ 2.59
Summary of Outstanding Options	Information on outstanding options as of June 30, 2023 is as follows: July July July July December January - July January July January May Range of ADS Exercise Price $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.60 $ 2.50 $ 1.80 $ 4.15 Weighted-average Remaining Contractual 1.0 2.0 3.0 4.24 7.46 7.71 8.51 9.01 9.52 9.84
Summary of Options Granted Price and Inputs	July July July July December January - July January July January May Grant-date ADS share price $ 6.80 $ 9.40 $ 11.30 $ 6.40 $ 11.10 $ 11.75 $ 5.60 $ 2.50 $ 1.80 $ 4.15 ADS Exercise price $ 6.80 $ 6.80 -$ 9.40 $ 11.30 $ 6.40 $ 2.60 $ 2.60 $ 2.60 $ 2.50 $ 1.80 $ 4.15 Expected volatility 50.86 % 36.37 % 39.34 % 38.33 % 66.25 % 118.1 % 122.1 % 118.2 % 133.5 % 130.5 % Expected life (years) 10 10 10 10 5.25 - 7 5.25 - 7 5.25 - 7 5.25 - 7 5.5 - 7 5.5 - 7 Risk-free interest rate 2.58 % 2.43 % 1.46 % 1.10 % 3.06 % 3.06 % 3.06 % 2.91 % 3.92 % 3.58 %
Summary of Long Term Incentive Plan	The Company’s LTIP is described as follows: For the six months ended June 30 Number of ADSs 2022 2023 Balance at January 1 144,146 144,146 Awards exercised — ( 20,000 ) Awards elapsed — ( 13,897 ) Balance at June 30 144,146 110,249 Balance exercisable, end of period 118,349 110,249

Reconciliation of Liabilities_2

Reconciliation of Liabilities Arising from Financing Activities (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of reconciliation of liabilities arising from financing activities [abstract]
Summary of Changes in Liabilities Arising from Financing Activities, Including Both Cash and Non-cash Changes	The table below details changes in the Company’s liabilities arising from financing activities, including both cash and non-cash changes. Liabilities arising from financing activities are those for which cash flows were, or future cash flows will be, classified in the Company’s consolidated statements of cash flows as cash flows from financing activities. Non-cash changes January 1, Interest Net Additions/ Others* Interest June 30, Lease Liabilities – current $ 199,124 ( 3,741 ) ( 149,007 ) — — 3,741 $ 50,117 Long-term borrowings (Note 12) $ 30,857,308 — 5,000,000 ( 1,044,027 ) ( 344,266 ) 1,951,024 $ 36,420,039 Interest payables (Note 11) $ 142,083 ( 996,355 ) — 1,044,027 — 5,556 $ 195,313 Non-cash changes January 1, Interest Net Additions/ Others* Interest June 30, Lease Liabilities – current $ 215,671 ( 7,207 ) ( 147,457 ) — — 7,207 $ 68,214 Long-term borrowings (Note 12) $ 29,656,133 ( 1,612,673 ) — ( 5,633,528 ) ( 125,279 ) 2,191,882 $ 24,476,535 Current borrowings (Note 12) $ 7,748,831 — — 5,633,528 — — $ 13,382,359 Financial liabilities at fair value through profit or loss**** $ 90,213 — 3,465,180 — ( 1,365,984 ) — $ 2,189,409 * Others comprise mainly foreign currency translation differences for long-term borrowings and net gain on fair value changes for financial liabilities measured at fair value through profit or loss. ** Transfer from long-term borrowings represented reclassified the current portion of the long-term borrowing to current borrowing. *** The Company classified interest paid arising from leases into financing cash flows activities and interest paid to non-related parties arising from borrowings into operating cash flows activities which is under the Company’s accounting policy which is consistently applied. **** Net proceeds arising from financial liabilities at fair value through profit or loss represented transfer of fair value for warrants at inception.

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of detailed information about financial instruments [abstract]
Fair Value of Financial Instruments Measured at Fair Value on Recurring Basis	December 31, 2022 Level 1 Level 2 Level 3 Total Financial assets at fair value through profit or loss Money Market Fund $ 30,445,339 $ — $ — $ 30,445,339 Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants $ — $ — $ 90,213 $ 90,213 June 30, 2023 Level 1 Level 2 Level 3 Total Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants $ — $ — $ 704,851 $ 704,851 Derivative financial liabilities – Tranche 1B Warrants $ — $ — $ 14,758 $ 14,758 Derivative financial liabilities – Tranche 2B Warrants $ — $ — $ 1,469,800 $ 1,469,800 Total $ — $ — $ 2,189,409 $ 2,189,409
Summary of Valuation Techniques and Inputs Applied for Level 3 Fair Value Measurement	Valuation Methodology Remaining Contractual Life (years) Historical Volatility December 31, 2022 June 30, 2023 December 31, 2022 June 30, 2023 Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants Binomial Tree 8.53 8.03 132.9 % 128.6 % Derivative financial liabilities – Tranche 1B Warrants Monte Carlo — 0.18 — 57.5 % Derivative financial liabilities – Tranche 2B Warrants Monte Carlo — 1.08 - 1.67 — 83.4 % - 91.3 %
Summary of Categories of Financial Instruments	December 31, June 30, 2022 2023 Financial assets Financial assets at fair value through profit or loss Money market fund $ 30,445,339 $ — Financial assets at amortized cost (1) $ 27,490,152 $ 53,970,737 Financial liabilities Financial liabilities at fair value through profit or loss Derivative financial liabilities – K2 warrants $ 90,213 $ 704,851 Derivative financial liabilities – Tranche 1B Warrants $ — $ 14,758 Derivative financial liabilities – Tranche 2B Warrants $ — $ 1,469,800 $ 90,213 $ 2,189,409 Financial liabilities at amortized cost (2) $ 41,922,924 $ 46,098,591 Equity instruments Equity instruments Pre-Funded Warrants $ — $ 8,262,698 Tranche 1A Warrants $ — $ 1,539,117 Tranche 2A Warrants $ — $ 2,173,285 $ — $ 11,975,100 1) The balances include financial assets at amortized cost, which comprise of cash and cash equivalents, trade receivable and refundable deposits. 2) The balances include financial liabilities at amortized cost, which comprise of trade payables, partial other payables, other current liabilities and long-term borrowings.
Summary of Significant Financial Assets and Liabilities Denominated in Foreign Currencies	The Company’s significant financial assets and liabilities denominated in foreign currencies were as follows: December 31, 2022 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 2,312,357 0.7461 $ 1,725,279 AUD A $ 2,616,802 0.6820 $ 1,784,606 Financial liabilities Monetary items SGD S $ 16,298,191 0.7461 $ 12,160,288 June 30, 2023 Foreign Exchange Carrying Financial assets Monetary items SGD S $ 1,707,639 0.7329 $ 1,251,462 AUD A $ 1,463,565 0.6642 $ 972,042 Financial liabilities Monetary items SGD S $ 16,649,298 0.7329 $ 12,201,621
Sensitivity Analysis of Foreign Currency Risk	For the six months ended June 30 2022 2023 Profit or loss* SGD $ ( 499,773 ) $ ( 547,508 ) AUD $ — $ 41,451 * This is mainly attributable to the exposure to outstanding deposits in banks and loans in foreign currency at the end of the reporting period.

Transactions with Related Par_2

Transactions with Related Parties (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of transactions between related parties [abstract]
Disclosure of Transactions Between Group and Other Related Parties	a. Related party name and category Related Party Name Related Party Category Others Key Management Personnel
Schedule of Key Management Personnel Compensation	b. Compensation of Key Management Personnel For the six months ended June 30 2022 2023 Short-term employee benefits $ 1,102,592 $ 1,180,189 Post-employment benefits 242,554 72,292 Share-based payments recognized 602,988 952,388 $ 1,948,134 $ 2,204,869

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2023
Disclosure of operating segments [abstract]
Analysis of the Company Revenue from Major Products and Services	The Company has only one reportable operating segment, and therefore, the reportable segment information is the same as the financial statements. The following is an analysis of the Company’s revenue from its major products and services. For the six months ended June 30 2022 2023 Out-licensing $ — $ 12,000,000

Application of New Amended an_3

Application of New Amended and Revised Standards and Interpretations - Schedule of New Amended or Revised Standards and Interpretations (Detail)	6 Months Ended
	Jun. 30, 2023
IFRS 10 and IAS 28 (amendments)
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	IFRS 10 and IAS 28 (amendments)
Description of nature of impending change in accounting policy	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
Amendments to IAS 1
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IAS 1
Description of nature of impending change in accounting policy	Classification of Liabilities as Current or Non-current
Amendments to IAS 1
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IAS 1
Description of nature of impending change in accounting policy	Non-current Liabilities with Covenants
Amendments to IFRS 16
Description Of Expected Impact Of Initial Application Of New Standards Or Interpretations [Line Items]
New, Amended or Revised Standards and Interpretations	Amendments to IFRS 16
Description of nature of impending change in accounting policy	Lease Liability in a Sale and Leaseback

Cash and Cash Equivalents - Sum

Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Cash and cash equivalents [abstract]
Cash in hand	$ 1,095	$ 256
Cash in banks	40,942,854	26,456,482
Money market fund		30,445,339
Cash	$ 40,943,949	$ 56,902,077

Trade Receivable - Summary of T

Trade Receivable - Summary of Trade Receivable (Detail)	Jun. 30, 2023 USD ($)
Trade and other receivables [abstract]
Trade receivables	$ 12,000,000
Total	$ 12,000,000

Other Assets - Summary of Other

Other Assets - Summary of Other Assets (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Other Assets Current And Non Current [Abstract]
Prepayments	$ 1,108,278	$ 2,942,936
Refundable deposits	1,026,789	1,033,414
Other current assets	$ 2,135,067	$ 3,976,350

Subsidiaries and Associate - Su

Subsidiaries and Associate - Summary of Subsidiaries and Associate Included in Consolidated Financial Statements (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
ASLAN Pharmaceuticals Pte. Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Limited
Name of Investee	ASLAN Pharmaceuticals Pte. Ltd.
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals (USA) Inc.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of Investee	ASLAN Pharmaceuticals (USA) Inc.
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals Australia Pty Ltd
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of Investee	ASLAN Pharmaceuticals Australia Pty Ltd
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals Hong Kong Limited
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of Investee	ASLAN Pharmaceuticals Hong Kong Limited
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
ASLAN Pharmaceuticals (Shanghai) Co. Ltd.
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Hong Kong Limited
Name of Investee	ASLAN Pharmaceuticals (Shanghai) Co. Ltd.
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	100%	100%
Jaguahr Therapeutics Pte. Ltd
Disclosure Of Significant Investments In Subsidiaries [Line Items]
Name of Investor	ASLAN Pharmaceuticals Pte. Ltd.
Name of associate	Jaguahr Therapeutics Pte. Ltd. (“JAGUAHR”)
Nature of Activities	New drug researchand development
Proportion of Ownership (%)	35%	35%

Investment in Associate Compa_3

Investment in Associate Company - Summary of Subsidiaries That Have Material Non-controlling Interests (Detail) - Jaguahr Therapeutics Pte.Ltd.	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Disclosure of subsidiaries [line items]
Name of Subsidiary	Jaguahr Therapeutics Pte. Ltd.
Principal Place of Business	Singapore
Proportion of Ownership and Voting Rights Held by the Company	35%	35%

Investment in Associate Compa_4

Investment in Associate Company - Summary of Financial Information Before Intragroup Eliminations (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Disclosure of subsidiaries [line items]
Current assets	$ 55,079,016	$ 60,878,427
Current liabilities	(24,358,487)	(23,164,238)
Equity/(Capital deficiency)	6,370,835	8,365,220	$ 32,668,712	$ 57,303,743
Jaguahr Therapeutics Pte.Ltd.
Disclosure of subsidiaries [line items]
Current assets	1,173	54,906
Current liabilities	(25,984)	(30,371)
Equity/(Capital deficiency)	$ (24,811)	$ 24,535

Investment in Associate Compa_5

Investment in Associate Company - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Disclosure Of Significant Investments In Associates [Line Items]
Loss for the period	$ (20,467,479)	$ (24,194,095)
Net cash outflow from operating activities	(37,329,318)	(16,912,283)
Investments in associates	0		$ 8,587
Liability recognized in associate	0
Jaguahr Therapeutics Pte. Ltd
Disclosure Of Significant Investments In Associates [Line Items]
Loss for the period	49,346	892,490
Net cash outflow from operating activities	53,733	548,336
Investment losses in associate	8,587	$ 486,141
Investments in associates	$ 0		$ 8,587

Trade And Other Payables - Addi

Trade And Other Payables - Additional Information (Details) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Trade and other payables [abstract]
Trade payables	$ 6,304,936	$ 12,784,485

Trade And Other Payables - Sche

Trade And Other Payables - Schedule of Other Payables (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Trade and other payables [abstract]
Payables for cash-settled long-term incentive plan	$ 478,808	$ 234,448
Payables for salaries and bonuses	873,768	1,375,627
Payables for professional fees	767,368	560,578
Others	293,625	154,385
Ending balance	2,413,569	2,325,038
Maturity analysis:
On demand or within 1 year	$ 2,413,569	$ 2,325,038

Borrowings - Summary of Loans (

Borrowings - Summary of Loans (Detail) $ in Millions	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)	Apr. 27, 2011 SGD ($)
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	$ 24,476,535	$ 29,656,133
Total borrowings	37,858,894	37,404,964
Not Later Than One Year
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	13,382,359	7,748,831
Later Than One Year
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	24,476,535	29,656,133
Loan from Government
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured	11,952,656	11,855,579	$ 10
Other Long-term Borrowings
Disclosure Of Detailed Information About Borrowings [Line Items]
Total borrowings	$ 25,906,238	$ 25,549,385

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) $ / shares in Units, $ in Millions				6 Months Ended		12 Months Ended
	Jan. 05, 2022 USD ($) $ / shares shares	Jul. 12, 2021 USD ($) $ / shares	Apr. 27, 2011 SGD ($)	Jun. 30, 2023 USD ($) Warrant $ / shares	Jun. 30, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured				$ 24,476,535		$ 29,656,133
Long term borrowings				$ 37,858,894		$ 37,404,964
Warrant price per share | $ / shares				$ 0.01		$ 0.01
Loans from Government
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured			$ 10	$ 11,952,656		$ 11,855,579
Loan repayable period			five-year
Borrowings, interest rate			6%
Loans from Government
Disclosure Of Detailed Information About Borrowings [Line Items]
Long-term borrowings - unsecured				$ 11,952,656		11,855,579
Two H V Loan Agreement [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Borrowings, interest rate	2.95%
Number of other equity instruments exercised or vested in share-based payment arrangement | Warrant				0
Two H V Loan Agreement [Member] | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Proceeds from non-current borrowings	$ 5,000,000
Two H V Loan Agreement [Member] | Ordinary Shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant price per share | $ / shares	$ 0.5257
Two H V Loan Agreement [Member] | Ordinary Shares | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Number Of Shares Exercisable Under The Warrants | shares	1,402,891
Two H V Loan Agreement [Member] | American Depositary Share
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant price per share | $ / shares	$ 13.1425
Two H V Loan Agreement [Member] | American Depositary Share | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Number Of Shares Exercisable Under The Warrants | shares	56,116
Two H V Loan Agreement [Member] | Top of Range [Member] | Second Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Proceeds from non-current borrowings	$ 25,000,000
K2HV Loan Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Loan repayable period		July 12, 2031
Borrowings, interest rate		2.95%
Term loans bear prime interest rate		plus 5.00%
Term loans annual interest rate		8.25%
Term loans monthly interest only payments, period		until August 1, 2023
Term loans monthly interest only payments, Extension period		Aug. 01, 2024
Term loan maturity date		Jul. 01, 2025
Facility fee		$ 255,000
Percentage of additional facility fee		0.85%
Percentage of final payment fee		6.25%
Percentage of prepayment fee		3%
Fair value of first tranche loan		$ 19,311,676
Proceeds from warrant		688,324
Fair value of warrants				$ 704,851		$ 90,213
Fair value (gain)/loss of warrants				$ 614,638	$ (104,001)
K2HV Loan Agreement | First Tranche [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Current borrowings		20,000,000
K2HV Loan Agreement | Second and Third Tranche
Disclosure Of Detailed Information About Borrowings [Line Items]
Current borrowings		10,000,000
K2HV Loan Agreement | Fourth Tranche
Disclosure Of Detailed Information About Borrowings [Line Items]
Maximum borrowings		$ 15,000,000
K2HV Loan Agreement | Ordinary Shares
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant price per share | $ / shares		$ 0.5257		$ 0.1447
K2HV Loan Agreement | American Depositary Share
Disclosure Of Detailed Information About Borrowings [Line Items]
Warrant price per share | $ / shares		$ 13.1425		$ 3.6175
K2HV Loan Agreement | Top of Range [Member]
Disclosure Of Detailed Information About Borrowings [Line Items]
Long term borrowings		$ 45,000,000

Equity - Schedule of Ordinary S

Equity - Schedule of Ordinary Shares (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares authorised	1,000,000,000	500,000,000
Authorized par value per share	$ 0.01	$ 0.01
Number of ordinary shares issued and fully paid		13,948,935
Amount of share capital par value issued and fully paid	$ 63,700,842	$ 63,019,962
Ordinary Shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares issued and fully paid	416,811,380	348,723,365
American Depositary Share
Disclosure Of Classes Of Share Capital [Line Items]
Number of ordinary shares issued and fully paid	16,672,455
Ordinary Surplus [Member]
Disclosure Of Classes Of Share Capital [Line Items]
Amount of share capital surplus issued and fully paid	$ 218,233,378	$ 213,098,729

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($)			6 Months Ended
	Feb. 27, 2023	Feb. 24, 2023	Jun. 30, 2023	Dec. 31, 2022
Net Proceeds from offering of shares		$ 20,000,000	$ 21,255,809
Number of ordinary shares authorised			1,000,000,000	500,000,000
Warrant price per share			$ 0.01	$ 0.01
ATM Sales Agreement [Member] | Jefferies LLC
Net Proceeds from offering of shares			$ 1,200,000
Purchase Agreement
Warrant price per share		$ 4.4475
Private Placement
Proceeds from exercise of warrants	$ 20,000,000
Number of warrants exercisable			0
Pre-funded warrants value	$ 8,262,698
Gain (loss) fair value valuation of warrants			$ 1,980,622
Ordinary Shares
Number of shares fully paid			416,811,380
Ordinary Shares | ATM Sales Agreement [Member] | Jefferies LLC
Number of shares issued			8,130,150
Ordinary Shares | Purchase Agreement
Number of shares issued	59,957,865	112,359,550	170,263,320
Number of additional shares issued	52,401,685
Offering price per share		$ 0.178
Ordinary Shares | Private Placement
Number of shares issued in settlement of pre funded warrants		52,401,685
Fixed consideration of pre-funded warrants		$ 5,240
Ordinary Shares | Employee Stock Options
Number of shares exercised			18,910,875
American Depositary Share | ATM Sales Agreement [Member] | Jefferies LLC
Number of shares issued			325,206
American Depositary Share | Purchase Agreement
Number of shares issued	2,398,315	25	6,810,533
Number of additional shares issued	2,096,068
Offering price per share		$ 4.45
Warrant price per share		$ 4.4475
Percentage of share premium		15%
American Depositary Share | Private Placement
Number of warrants exercisable		11,061,823
Additional amount from exercise of warrants		$ 80,000,000
Number of shares issued in settlement of pre funded warrants		2,096,068
American Depositary Share | Employee Stock Options
Number of shares exercised			756,435
American Depositary Share | Purchase Agreement
Number of shares issued		4,494,382
Tranche 1A Warrants | Private Placement
Percentage of warrants exercisable until 60 days		50%
Pre-funded warrants value	$ 1,539,117
Tranche 1A Warrants | American Depositary Share
Percentage of warrants exercisable until 60 days		50%
Warrant exercise price		$ 6.5
Tranche 1B Warrants | Private Placement
Pre-funded warrants value	$ 1,539,897
Pre funded warrants fair value revalued amount			$ 14,758
Tranche 1B Warrants | American Depositary Share
Warrant exercise price		$ 6.5
Discount rate on warrant exercise price		50%
Tranche 1B Warrants | American Depositary Share | Private Placement
Discount rate on warrant exercise price	50%
Tranche 2A Warrants | Private Placement
Pre-funded warrants value	$ 2,173,285
Tranche 2A Warrants | American Depositary Share | Private Placement
Percentage of warrants exercisable until 60 days		50%
Warrant exercise price		$ 8.15
Tranche 2B Warrants | Private Placement
Pre-funded warrants value	$ 1,925,283
Pre funded warrants fair value revalued amount			$ 1,469,800
Tranche 2B Warrants | American Depositary Share
Percentage of warrants exercisable until 60 days		50%
Tranche 2B Warrants | American Depositary Share | Private Placement
Discount rate on warrant exercise price	50%	50%
Tranche 2B Warrants | American Depositary Share | Private Placement | Bottom of Range [Member]
Warrant exercise price		$ 8.15

Loss Before Income Tax - Summar

Loss Before Income Tax - Summary of General and Administrative Expenses (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Selling, general and administrative expense [abstract]
General and administrative expense	$ 6,814,831	$ 4,855,050

Loss Before Income Tax - Summ_2

Loss Before Income Tax - Summary of Research and Development Expenses (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Material income and expense [abstract]
Research and development expense	$ 25,652,648	$ 19,339,045

Loss Before Income Tax - Summ_3

Loss Before Income Tax - Summary of Finance costs (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Profit (loss) [abstract]
Interest on government loans	$ 222,357	$ 218,337
Interest on K2HV borrowing	1,969,525	1,732,687
Interest on lease liabilities	7,207	3,741
Other interest expenses	3,252	5,556
Finance costs	$ 2,202,341	$ 1,960,321

Loss Before Income Tax - Schedu

Loss Before Income Tax - Schedule of Depreciation and Amortization (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 180,847	$ 142,552
Right-of-Use Assets
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	166,404	134,402
Property, Plant and Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	12,383	8,090
Intangible Assets
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 2,060	$ 2,060

Loss Before Income Tax - Sche_2

Loss Before Income Tax - Schedule of Employee Benefits Expense (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Profit (loss) [abstract]
Short-term benefits	$ 5,477,372	$ 4,900,660
Post-employment benefits	257,692	200,712
Share-based payments
Equity-settled	1,212,832	1,336,637
Cash-settled	244,360	(380,964)
Total employee benefits expense	7,192,256	6,057,045
Employee benefits expense by function
General and administrative expenses	3,897,264	2,997,087
Research and development expenses	3,294,992	3,059,958
Total employee benefits expense	$ 7,192,256	$ 6,057,045

Loss Before Income Tax - Sche_3

Loss Before Income Tax - Schedule of Other Gains and Losses (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Profit (loss) [abstract]
Net gain on fair value changes of financial liabilities at fair value through profit or loss (Notes 12 and 13)	$ 1,365,984	$ 104,001
Net foreign exchange gain	6,102	256,084
Others	(20,366)	(15,402)
Other gains and losses	$ 1,351,720	$ 344,683

Income Taxe Expense - Summary o

Income Taxe Expense - Summary of Income Tax Recognised in Profit or Loss (Detail)	6 Months Ended
	Jun. 30, 2023 USD ($)
Current tax expenses
In respect of current period	$ 64,751

Income Tax Expense - Additional

Income Tax Expense - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ (20,933,095)	$ (25,971,668)
Accumulated unused tax losses	256,000,000	238,000,000
Accumulated deficit	(299,384,595)		$ (278,386,749)
Provision for income tax	$ 64,751
Singapore
Major Components Of Tax Expense Income [Line Items]
Statutory corporate income tax rate	17%
Provision for income tax	$ 0
Singapore | ASLAN Pharmaceuticals Pte. Ltd.
Major Components Of Tax Expense Income [Line Items]
Taxable income	0	0
Australia
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 0	0
Statutory corporate income tax rate	30%
Provision for income tax	$ 0
Hong Kong
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 0	0
Statutory corporate income tax rate	16.50%
Provision for income tax	$ 0
China
Major Components Of Tax Expense Income [Line Items]
Taxable income	$ 0	0
Statutory corporate income tax rate	25%
Provision for income tax	$ 0
UNITED STATES
Major Components Of Tax Expense Income [Line Items]
Provision for income tax	64,751	$ 70,000
Income tax expense prepaid	$ 63,500
Federal income tax rate	21%
State income tax rate	8.70%

Loss Per Ordinary Share - Summa

Loss Per Ordinary Share - Summary of Earnings Per Share (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Line Items]
Basic loss per ordinary share	$ (0.05)	$ (0.07)
Diluted loss per ordinary share	(0.05)	(0.07)
Ordinary Share
Earnings Per Share [Line Items]
Basic loss per ordinary share	(0.05)	(0.07)
Diluted loss per ordinary share	(0.05)	(0.07)
American Depositary Share
Earnings Per Share [Line Items]
Basic loss per ordinary share	(1.34)	(1.86)
Diluted loss per ordinary share	$ (1.34)	$ (1.86)

Loss Per Ordinary Share - Sum_2

Loss Per Ordinary Share - Summary of Loss and Weighted Average Number of Ordinary Shares Outstanding (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Earnings Per Share [Line Items]
Loss used in the computation of basic and diluted loss per share	$ (20,997,846)	$ (25,971,668)
Ordinary Shares
Earnings Per Share [Line Items]
Weighted-average number of ordinary shares in the computation of basic loss per ordinary share	391,014,637	348,723,365
American Depositary Share
Earnings Per Share [Line Items]
Weighted-average number of ordinary shares in the computation of basic loss per ordinary share	15,640,585	13,948,935

Share-based Payment Arrangeme_3

Share-based Payment Arrangements - Additional Information (Detail)

1 Months Ended

6 Months Ended

7 Months Ended

12 Months Ended

May 01, 2023 shares

Jan. 01, 2023 shares

Jul. 01, 2022 shares

Jan. 01, 2022 shares

Dec. 15, 2020 shares

Dec. 10, 2020 shares

Jul. 30, 2019 shares

Jul. 30, 2018 shares

Feb. 01, 2018 shares

Aug. 23, 2017 shares

May 31, 2023 $ / shares

Jan. 31, 2023 $ / shares

Jul. 31, 2022 USD ($) $ / shares

Jan. 31, 2022 $ / shares

Dec. 31, 2020 $ / shares

Sep. 30, 2017 shares

Jul. 31, 2017 $ / shares

Jul. 31, 2016 $ / shares

Jul. 31, 2014 $ / shares

Jul. 31, 2010 shares

Jun. 30, 2023 USD ($) shares

Jun. 30, 2022 USD ($) shares

Jul. 31, 2021 $ / shares

Dec. 31, 2022 USD ($) shares

Dec. 31, 2021 shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

ADS Exercise price | $ / shares

$ 4.15

$ 1.8

$ 2.5

$ 2.6

$ 2.6

$ 6.4

$ 11.3

$ 6.8

$ 2.6

Incremental fair value recognised | $

$ 279,636

Compensation costs recognised | $

$ 1,212,832

$ 1,336,637

Other Payable

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Recognized compensation liabilities, Current | $

$ 478,808

$ 234,448

American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Maximum number of ordinary shares issued

827,079

2,481,237

Long term incentive plan bonus entitlement units granted

4,160

58,480

2014 Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

6,670,356

Share option granted expiration period

10 years

Share based payment, vesting period

4 years

Vesting description

If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.

2014 Plan | Ordinary Shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

13,340,712

2014 Plan | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

533,629

2020 Equity Incentive Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Share option granted expiration period

10 years

10 years

Maximum number of ordinary shares issued

20,676,974

62,030,922

Share based payment, vesting period

4 years

Issuance of new share capital, shares

13,948,935

13,948,935

Percentage of increase in outstanding shares

4%

4%

4%

Vesting description

If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.

2020 Equity Incentive Plan | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

370,000

407,226

143,600

355,030

764,812

777,226

355,030

56,400

Issuance of new share capital, shares

557,958

557,958

ADS Exercise price | $ / shares

$ 2.6

2017 Plan

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

825,833

Share option granted expiration period

10 years

Share based payment, vesting period

2 years

Vesting description

If the options remain unexercised after a period of ten years from the date of grant, the options expire. Options are forfeited if the employee leaves the Company before the options vest.

2017 Plan | Ordinary Shares

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

825,833

2017 Plan | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Option granted

33,033

Long Term Incentive Plan Granted in 2017

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

104,000

1,462,000

Long Term Incentive Plan Granted in 2018

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

98,204

48,228

Long Term Incentive Plans

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Number of units forfeited

13,897

0

Reporting date fair value of award | $

$ 3.65

Recognised total (expense) benefit | $

$ (244,360)

$ 380,964

Long Term Incentive Plans | American Depositary Share

Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]

Long term incentive plan bonus entitlement units granted

110,249

Number of units forfeited

56,700

Number of units redeemed

42,123

Share-based Payment Arrangeme_4

Share-based Payment Arrangements - Summary of Employee Share Options (Detail)						1 Months Ended		6 Months Ended		12 Months Ended
	May 01, 2023 shares	Jan. 01, 2023 shares $ / shares	Jul. 01, 2022 shares $ / shares	Jan. 01, 2022 shares $ / shares	Dec. 15, 2020 shares	Sep. 30, 2017 shares	Jul. 31, 2010 shares	Jun. 30, 2023 shares $ / shares	Jun. 30, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
2014 Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Equivalent ADSs granted							6,670,356
2014 Plan | American Depositary Share
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Beginning of Period		371,569	371,569	487,829				371,569	487,829
Number of Equivalent ADSs, Equivalent ADSs expired								(48,800)	(116,260)
Number of Equivalent ADSs, Equivalent ADSs granted							533,629
Number of Equivalent ADSs, Ending of Period								322,769	371,569	487,829
Number of Equivalent ADSs, Equivalent ADS exercisable, end of period								322,769	371,569
Weighted- average Exercise Price, Beginning of Period | $ / shares		$ 22	$ 22	$ 17.88				$ 22	$ 17.88
Weighted- average Exercise Price, Equivalent ADSs expired | $ / shares								17.08	17.08
Weighted- average Exercise Price, End of Period | $ / shares								22.74	22	$ 17.88
Weighted- average Exercise Price, Equivalent ADSs exercisable, end of period | $ / shares								$ 22.74	$ 22
2017 Plan
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Equivalent ADSs granted						825,833
2017 Plan | American Depositary Share
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Beginning of Period		20,048	20,048	20,048				20,048	20,048
Number of Equivalent ADSs, Equivalent ADSs granted						33,033
Number of Equivalent ADSs, Equivalent ADSs forfeited								(333)	0
Number of Equivalent ADSs, Ending of Period								19,715	20,048	20,048
Number of Equivalent ADSs, Equivalent ADS exercisable, end of period								19,715	20,048
Weighted- average Exercise Price, Beginning of Period | $ / shares		$ 31.9	$ 31.9	$ 31.9				$ 31.9	$ 31.9
Weighted- average Exercise Price, Equivalent ADSs forfeited | $ / shares								31.9	0
Weighted- average Exercise Price, End of Period | $ / shares								31.9	31.9	$ 31.9
Weighted- average Exercise Price, Equivalent ADSs exercisable, end of period | $ / shares								$ 31.9	$ 31.9
2020 Equity Incentive Plan | American Depositary Share
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of Equivalent ADSs, Beginning of Period		1,154,072	1,010,468	804,313				1,154,072	804,313
Number of Equivalent ADSs, Equivalent ADSs granted	370,000	407,226	143,600	355,030	764,812			777,226	355,030	56,400
Number of Equivalent ADSs, Equivalent ADSs forfeited								0	(148,875)
Number of Equivalent ADSs, Ending of Period								1,931,298	1,010,468	804,313
Number of Equivalent ADSs, Equivalent ADS exercisable, end of period								673,880	241,205
Weighted- average Exercise Price, Beginning of Period | $ / shares		$ 2.59	$ 8.65	$ 10.3				$ 2.59	$ 10.3
Weighted- average Exercise Price, Equivalent ADSs granted | $ / shares								2.92	5.6
Weighted- average Exercise Price, Equivalent ADSs forfeited | $ / shares								0	10.3
Weighted- average Exercise Price, End of Period | $ / shares								2.72	8.65	$ 10.3
Weighted- average Exercise Price, Equivalent ADSs exercisable, end of period | $ / shares								$ 2.59	$ 8.65

Share-based Payment Arrangeme_5

Share-based Payment Arrangements - Summary of Outstanding Options (Detail)	6 Months Ended
	Jun. 30, 2023 $ / shares
July 2014
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 6.8
Weighted-average Remaining Contractual Life (Years)	1 year
July 2015
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Weighted-average Remaining Contractual Life (Years)	2 years
July 2015 | Top of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 9.4
July 2015 | Bottom of Range [Member]
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	6.8
July 2016
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 11.3
Weighted-average Remaining Contractual Life (Years)	3 years
July 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 6.4
Weighted-average Remaining Contractual Life (Years)	4 years 2 months 26 days
December 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 2.6
Weighted-average Remaining Contractual Life (Years)	7 years 5 months 15 days
January-July 2021
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 2.6
Weighted-average Remaining Contractual Life (Years)	7 years 8 months 15 days
January 2022
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 2.6
Weighted-average Remaining Contractual Life (Years)	8 years 6 months 3 days
July 2022
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 2.5
Weighted-average Remaining Contractual Life (Years)	9 years 3 days
January 2023
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 1.8
Weighted-average Remaining Contractual Life (Years)	9 years 6 months 7 days
May 2023
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Range of ADS Exercise Price	$ 4.15
Weighted-average Remaining Contractual Life (Years)	9 years 10 months 2 days

Share-based Payment Arrangeme_6

Share-based Payment Arrangements - Summary of Options Granted Price and Inputs (Detail)	1 Months Ended									7 Months Ended
	May 31, 2023 yr $ / shares	Jan. 31, 2023 yr $ / shares	Jul. 31, 2022 yr $ / shares	Jan. 31, 2022 yr $ / shares	Dec. 31, 2020 yr $ / shares	Jul. 31, 2017 yr $ / shares	Jul. 31, 2016 yr $ / shares	Jul. 31, 2015 yr $ / shares	Jul. 31, 2014 yr $ / shares	Jul. 31, 2021 yr $ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Grant-date ADS share price	$ 4.15	$ 1.8	$ 2.5	$ 5.6	$ 11.1	$ 6.4	$ 11.3	$ 9.4	$ 6.8	$ 11.75
ADS Exercise price	$ 4.15	$ 1.8	$ 2.5	$ 2.6	$ 2.6	$ 6.4	$ 11.3		$ 6.8	$ 2.6
Expected volatility	130.50%	133.50%	118.20%	122.10%	66.25%	38.33%	39.34%	36.37%	50.86%	118.10%
Expected life | yr						10	10	10	10
Risk-free interest rate						1.10%	1.46%	2.43%	2.58%
Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
ADS Exercise price								$ 6.8
Expected life | yr	5.5	5.5	5.25	5.25	5.25					5.25
Risk-free interest rate	3.58%	3.92%	2.91%	3.06%	3.06%					3.06%
Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
ADS Exercise price								$ 9.4
Expected life | yr	7	7	7	7	7					7
Risk-free interest rate	3.58%	3.92%	2.91%	3.06%	3.06%					3.06%

Share-based Payment Arrangeme_7

Share-based Payment Arrangements - Summary of Long Term Incentive Plan (Detail) - Long Term Incentive Plans - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	144,146	144,146
Awards exercised	(20,000)	0
Awards elapsed	(13,897)	0
Ending balance	110,249	144,146
Balance exercisable, end of period	110,249	118,349

Reconciliation of Liabilities_3

Reconciliation of Liabilities Arising from Financing Activities - Summary of Changes in Liabilities Arising from Financing Activities, Including Both Cash and Non-cash Changes (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Net proceeds / (repayment)	$ 21,101,145	$ 4,850,993
Lease Liabilities Current
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	215,671	199,124
Interest paid	(7,207)	(3,741)
Net proceeds / (repayment)	(147,457)	(149,007)
Interest expense	7,207	3,741
Liabilities arising from financing activities	68,214	50,117
Current Borrowings
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	7,748,831
Additions / (Transfer)	5,633,528
Liabilities arising from financing activities	13,382,359
Long-Term Borrowings
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	29,656,133	30,857,308
Interest paid	(1,612,673)
Net proceeds / (repayment)		5,000,000
Additions / (Transfer)	(5,633,528)	(1,044,027)
Others	(125,279)	(344,266)
Interest expense	2,191,882	1,951,024
Liabilities arising from financing activities	24,476,535	36,420,039
Interest Payables
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities		142,083
Interest paid		(996,355)
Additions / (Transfer)		1,044,027
Interest expense		5,556
Liabilities arising from financing activities		$ 195,313
Financial Liabilities at Fair Value Through Profit or Loss
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Liabilities arising from financing activities	90,213
Net proceeds / (repayment)	3,465,180
Others	(1,365,984)
Liabilities arising from financing activities	$ 2,189,409

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	$ 2,189,409	$ 90,213
Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	2,189,409	90,213
Money Market Fund [Member]
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Money Market Fund [Member] | Fair Value Measured on Recurring Basis
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
K2 Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	704,851	90,213
K2 Warrants | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	704,851
Tranche 1B Warrants | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	14,758
Tranche 2B Warrants
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	1,469,800
Tranche 2B Warrants | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	1,469,800
Level 1 | Money Market Fund [Member] | Fair Value Measured on Recurring Basis
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss		30,445,339
Level 3 | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	2,189,409	$ 90,213
Level 3 | K2 Warrants | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	704,851
Level 3 | Tranche 1B Warrants | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	14,758
Level 3 | Tranche 2B Warrants | Fair Value Measured on Recurring Basis
Financial liabilities at fair value through profit or loss
Derivative financial liabilities	$ 1,469,800

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail)		6 Months Ended					12 Months Ended
	Feb. 24, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2023 SGD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 SGD ($)	Dec. 31, 2022 USD ($)
Disclosure Of Financial Instruments [Line Items]
Transfer between Level 1 and 2, assets		$ 0					$ 0
Transfer between Level 1 and 2, liabilities		0					0
Transfer between Level 2 and 1, Assets		0					0
Transfer between Level 2 and 1, liabilities		0					0
Transfers into Level 3 of fair value hierarchy, assets		0					0
Transfers out of Level 3 of fair value hierarchy, assets		0					0
Transfers into Level 3 of fair value hierarchy, liabilities		0					0
Transfers out of Level 3 of fair value hierarchy, liabilities		0					0
Money market fund							$ 30,445,339
Increase in pre-tax loss		378,589			$ 364,200
Net Proceeds from offering of shares	$ 20,000,000	$ 21,255,809
Addition To gross proceeds related to tranche warrants exercised	$ 80,000,000
Foreign Currency Risk
Disclosure Of Financial Instruments [Line Items]
Sensitivity rate used in reporting foreign currency risk		5%	5%	5%
Percentage of increase on exchange rate of foreign currency		5%	5%	5%
Percentage of decrease on exchange rate of foreign currency		5%	5%	5%
Impact of a 5% change in foreign exchange rates on profit or loss			$ (547,508)	$ 41,451		$ (499,773)
Interest Rate Risk
Disclosure Of Financial Instruments [Line Items]
Borrowings, interest rate basis		1%	1%	1%

Financial Instruments - Summary

Financial Instruments - Summary of Valuation Techniques and Inputs Applied for Level 3 Fair Value (Detail) - Level 3 - Historical volatility for shares, measurement input [member]	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
K2 Warrants | Binomial Tree
Disclosure Of Financial Instruments [Line Items]
Remaining Contractual Life (years)	8 years 10 days	8 years 6 months 10 days
Historical Volatility	128.60%	132.90%
Tranche 1B Warrants | Monte Carlo
Disclosure Of Financial Instruments [Line Items]
Remaining Contractual Life (years)	2 months 4 days
Historical Volatility	57.50%
Tranche 2B Warrants | Monte Carlo | Bottom of Range
Disclosure Of Financial Instruments [Line Items]
Remaining Contractual Life (years)	1 year 29 days
Historical Volatility	83.40%
Tranche 2B Warrants | Monte Carlo | Top of Range
Disclosure Of Financial Instruments [Line Items]
Remaining Contractual Life (years)	1 year 8 months 1 day
Historical Volatility	91.30%

Financial Instruments - Summa_2

Financial Instruments - Summary of Categories of Financial Instruments (Detail) - USD ($)		Jun. 30, 2023	Dec. 31, 2022
Financial assets at fair value through profit or loss
Financial assets at amortized cost	[1]	$ 53,970,737	$ 27,490,152
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		2,189,409	90,213
Financial liabilities at amortized cost	[2]	46,098,591	41,922,924
Equity instruments		11,975,100
Money Market Fund [Member]
Financial assets at fair value through profit or loss
Financial assets at fair value through profit or loss			30,445,339
K2 Warrants [Member]
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		704,851	$ 90,213
Tranche 2B Warrants [Member]
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		1,469,800
Pre-funded Warrants
Financial liabilities at fair value through profit or loss
Equity instruments		8,262,698
Tranche 1A Warrants [Member]
Financial liabilities at fair value through profit or loss
Equity instruments		1,539,117
Tranche 1B Warrants [Member]
Financial liabilities at fair value through profit or loss
Derivative financial liabilities		14,758
Tranche 2A Warrants
Financial liabilities at fair value through profit or loss
Equity instruments		$ 2,173,285
[1] The balances include financial assets at amortized cost, which comprise of cash and cash equivalents, trade receivable and refundable deposits. The balances include financial liabilities at amortized cost, which comprise of trade payables, partial other payables, other current liabilities and long-term borrowings.

Financial Instruments - Summa_3

Financial Instruments - Summary of Significant Financial Assets and Liabilities Denominated in Foreign Currencies (Detail)	6 Months Ended		12 Months Ended
	Jun. 30, 2023 SGD ($)	Jun. 30, 2023 SGD ($) AUD ($)	Dec. 31, 2022 SGD ($)	Dec. 31, 2022 SGD ($) AUD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 AUD ($)	Dec. 31, 2022 USD ($)
Disclosure of detailed information about financial instruments [abstract]
Financial assets, Foreign Currencies	$ 1,707,639	$ 1,707,639	$ 2,312,357	$ 2,312,357	$ 1,463,565		$ 2,616,802
Financial assets, Exchange Rate	0.7329	0.6642	0.7461	0.682
Financial assets, Carrying Amount	$ 1,251,462	$ 1,251,462	$ 1,725,279	$ 1,725,279	$ 972,042		$ 1,784,606
Financial liabilities, Foreign Currencies	$ 16,649,298	$ 16,649,298	$ 16,298,191	$ 16,298,191
Financial liabilities, Exchange Rate	0.7329		0.7461
Financial Liabilities, Carrying Amount						$ 12,201,621		$ 12,160,288

Financial Instruments - Sensiti

Financial Instruments - Sensitivity Analysis of Foreign Currency Risk (Detail)	6 Months Ended
	Jun. 30, 2023 SGD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 SGD ($)
Foreign Currency Risk
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items]
Impact of a 5% change in foreign exchange rates on profit or loss	$ (547,508)	$ 41,451	$ (499,773)

Transactions with Related Par_3

Transactions with Related Parties - Schedule of a Related Party Name and Category (Detail) - Key Management Personnel	6 Months Ended
	Jun. 30, 2023
Disclosure Of Transactions Between Related Parties [Line Items]
Related party name	Others
Related party category	Key Management Personnel

Transactions with Related Par_4

Transactions with Related Parties - Schedule of Key Management Personnel Compensation (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of transactions between related parties [abstract]
Short-term employee benefits	$ 1,180,189	$ 1,102,592
Post-employment benefits	72,292	242,554
Share-based payments recognized	952,388	602,988
Key management personnel compensation	$ 2,204,869	$ 1,948,134

Transactions with Related Par_5

Transactions with Related Parties - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Disclosure of transactions between related parties [abstract]
Remuneration of non-executive directors	$ 143,000	$ 116,833

Material License Agreements - A

Material License Agreements - Additional Information (Detail) - License Agreements $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Almirall
Disclosure Of Transactions Between Related Parties [Line Items]
Agreement date	Dec. 31, 2015
Agreement amended date	Mar. 31, 2018
CSL Limited
Disclosure Of Transactions Between Related Parties [Line Items]
First Payment	$ 30
Regulatory milestones linked payments estimated	95
Sales mile stones linked payments estimated	655
Zenyaku Kogyo Co., ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Non refundable upfront payment	12
Upfront Payment	$ 12
Top of Range [Member] | CSL Limited
Disclosure Of Transactions Between Related Parties [Line Items]
Percentage of entity's revenue	10%
Top of Range [Member] | Zenyaku Kogyo Co., ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Non refundable upfront payment receivable in development milestones	$ 29.5
Non refundable upfront payment receivable in commercial milestones	$ 94

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2023 USD ($) Segment
Disclosure Of Operating Segments [Line Items]
Number of reportable segment | Segment	1
Revenue	$ 12,000,000
Zenyaku Kogyo Co., ltd
Disclosure Of Operating Segments [Line Items]
Revenue	12,000,000
Out-licensing
Disclosure Of Operating Segments [Line Items]
Revenue	$ 12,000,000

Segment Reporting - Summary of

Segment Reporting - Summary of Analysis of Company's Revenue from Products and Services (Detail)	6 Months Ended
	Jun. 30, 2023 USD ($)
Disclosure of operating segments [line items]
Revenue	$ 12,000,000
Out-licensing
Disclosure of operating segments [line items]
Revenue	$ 12,000,000

Other Items_Subsequent Events -

Other Items/Subsequent Events - Additional Information (Detail)	Jul. 20, 2023 USD ($)
Purchase Agreement
Disclosure Of Nonadjusting Events After Reporting Period [Line Items]
Upfront payment	$ 12,000,000